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This kit is designed as an information and advocacy tool in response to
two new, legally-binding international agreements. 
• The Convention on Biological Diversity, adopted at the Rio Earth
Summit in 1992, came into force in December 1993. T h e
Biodiversity Convention affirms the sovereignty of nations over their
biological resources, but also accepts the concept of “intellectual
property” over living materials. 
• In June 1994, at Marakesh, the Uruguay Round of the General
Agreement on Ta r i ffs and Trade (GATT) was signed, and on January
1st, 1995 the World Trade Organization (WTO) came into being to
administer and monitor both the Uruguay document and the ongoing
process of global trade harmonization. For the first time, a global
trade accord contained explicit obligations for signatory states to
adopt legislation for intellectual property, including monopolies over
life forms. 
Although both these agreements have the force of international law,
there remains considerable flexibility in how governments might inter-
pret and implement their intellectual property provisions. Further, the
time frame for implementation permitted under the agreements is either
u n d e fined, or allows legislators considerable leeway well into the fir s t
decade of the next century.
With information about the debates that are occurring internationally,
non-governmental organizations (NGOs), farming people, and sympa-
thetic policy makers have an opportunity to influence national and inter-
national policy decisions on intellectual property that could have a pro-
found effect on the lives and livelihoods of people in the South. 
With this in mind, the kit is intended to be used mainly by two audiences:
1) Farming communities, agricultural NGOs and activists in the
S o u t h who wish to understand the (sometimes deliberately) confusing
debate over intellectual property and increase their background knowl-
edge of the key actors and issues.
2) Southern policy makers both inside and outside governments who
wish to join the debate on intellectual property will find the kit helpful
in suggesting entry points and means for influencing decisions at the
national and international levels. 
Governments must still negotiate definitions and potentially confli c t i n g
requirements concerning the innovative genius of indigenous communi-
ties and the Western concept of intellectual property. The debate over
these terms may well occupy the next decade of intergovernmental nego-
tiations and more information is needed to give governments and non-
governmental activists the tools to participate fully in these discussions.
USER’S GUIDE
Inside the kit, users will find the fol-
lowing information:
• a short history of the revolution in
intellectual monopolies
• practical definitions of the legal
terminology used
• an overview of different interpre-
tations of intellectual property
issues within the international
d e b a t e
• trends of concern to agricultural
producers and rural societies
• a description of international
organizations and meetings where
the intellectual property debate is
occuring. Boxes at the beginning
of each chapter give a short 
summary of its key contents and
arguments, and describe how the
chapter can be used. 
Tables, charts and maps throughout
the text give some information in
summary form. Other tables in
Appendices A, B, C, D, and E provide
more detailed information on specific
topics linked to the main text. 
Many key terms are presented in
b o l d type the first time they appear
in the text. Sidebars in the text give
short definitions of key terms used
for the first time. Detailed defin i t i o n s
are provided in the Glossary in
Appendix D. 
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This chapter summarizes the major issues
in the present debate on intellectual 
property, including
• the new industrial/agricultural revolu-
tion and its impact on life
• the new “enclosure of the commons”
by life industries
• the importance of global biodiversity
• the North’s dependence on Southern
genetic re s o u rces and knowledge 
systems
• how the knowledge of indigenous com-
munities is being lost and expropriated
• the definition of intellectual property 
• the role and scope of current global
a c c o rds that govern intellectual pro p e rt y
r i g h t s .
For additional information, see Appendix
A: A Short History of the Patent System,
showing some of the precedent-setting
incursions of intellectual property regimes
into different areas of life. 
Chapter 1I
The New Act of Enclosure
For most of history, security and the route to power have been invested
in land: land to graze animals, gather food and medicine, collect fuel
wood, and build shelters. In virtually every farming society, some por-
tion of the available land is set aside as “the commons” for the entire
c o m m u n i t y. Although there may be rules governing access to and use 
of the commons, often logically linked to seasonal or other biologically-
determined factors, they have remained outside of private ownership. 
This was the situation in Europe until the agricultural revolution in the
late 18th century, when powerful landlords, championing the cause of
s c i e n t i fic progress and claiming the need to feed the continent’s growing
population, persuaded the governments of the day to allow them to buy
the commons. What was not for governments to sell became the private
property of the already-rich. Within a matter of decades, landlords
fenced off the commons in a political coup that became infamous as 
the Acts of Enclosure. 
E u r o p e ’s farming communities lost much of their most important land.
Their access to forages and medicines was curtailed. Millions were driven
from their ancestral lands either to labour in the factory towns of the
new scientific revolution or to emigrate overseas to the Americas. 
Between 1770 (when Oliver Goldsmith wrote his tragic poem T h e
Deserted Vi l l a g e about the impact of the Acts of Enclosure) and 1850,
the British government granted almost 12,000 patents to inventors
financed by landlords made rich through the enclosures. In this way, 
the movement to enclose the land in 18th and 19th century Europe
financed the movement to enclose human minds.
In the late 20th century, we are now in the midst of a new “act of enclo-
sure” and on the threshold of another agricultural and industrial revolu-
tion. The new revolution combines microbiology (or b i o t e c h n o l o g y) and
micro-electronics (or informatics). The key to this micro-revolution lies
in its control of information, especially information in the life sciences.
The new act of enclosure is the intellectual pro p e rty (IP) system that
allows today’s “landlords” of technology to expropriate our intellectual
commons, which is the knowledge and skills of farming and indigenous
peoples both today and back through history.
The rationale for the new enclosure is disturbingly similar to the 
a rguments made by landlords in Europe two centuries ago: 
• A rapidly multiplying human population, say proponents of biotechnol-
o g y, is in danger of running out of food and of destroying the viability
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O V E RV I E W
A new industrial and agricultural rev-
olution is underway that enables the
private sector and transnational cor-
porations to create monopolies over
many biological processes and life
forms through the use of intellectual
p r o p e r t y. Intellectual property laws
now allow patents on living organ-
isms and can be used to privatize
indigenous knowledge. B i o d i v e r s i t y,
a diminishing resource, has been
adequately managed up to now by
many indigenous farming societies
and cultures. New life industries that
use biotechnology and operate
under intellectual property systems
are poised to take control of valuable
organisms and knowledge systems
under international accords such as
the Convention on Biological
Diversity/Biodiversity Convention
and the General Agreement on
Ta r i ffs and Trades (G AT T).
ENCLOSURES OF THE MIND 
An Introduction to Intellectual Monopolies
of the entire planet. New, expensive, research-intensive biotechnolo-
gies must be employed to feed the poor and protect the planet. 
• For the new biotechnologies to succeed, the private sector and trans-
national enterprises must be able to protect their massive research
investment through the creation of monopolies that will enable them
to control access to the inventions they generate on our behalf. Industry
advocates argue that corporate science needs patents, trademarks,
trade secrets, and plant breeders’ rights (all intellectual property
monopolies) in order to save the world from starvation.
Although many people have some understanding of computers and micro-
electronics that allow the manipulation of vast quantities of information,
most of us are less familiar with biotechnology. Biotechnology works
with the products, processes, and formulas of life. In the new biotech-
nologies, micro-organisms, plants, animals, and even human genetic
materials are merely raw materials to be manipulated, mixed and
matched for the production of new life products that might feed or 
cure us or clean up our polluted planet. When the power of computer
technologies to manage information is placed at the service of the life-
manipulation powers of biotechnology, industry can take charge of the
most powerful revolution in human history. When industry is allowed
exclusive monopoly control over life information through intellectual
p r o p e r t y, an “enclosure of the mind” occurs. 
Until recently, this subject was confined to industry boardrooms and to
an exclusive circle of trade negotiators. In light of recent international
agreements, the new enclosure system has assumed enormous impor-
tance for governments and people of the South. Forty percent of the
world economy is based upon biological products and processes. T h e
w o r l d ’s poor rely on biodiversity for 85% to 95% of their livelihoods.
All this is at stake in the global drive to allow the patenting of living
o rganisms. For farming and other rural communities, the struggle
against the new enclosures of the mind is a fight for survival. 
Enclosing Diversity
B i o d i v e r s i t y, once thought to be a bottomless bounty, is now a dimin-
ishing resource. Like any resource in the commercial world, scarcity
increases its value. As the so-called raw material of the new biotech-
nologies, biodiversity (specifically the genes and gene complexes within
diverse plant and animal species, m i c ro o r g a n i s m s , and even human
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biotechnology
Techniques that involve the use and manipulation
of living organisms to make commercial products.
Intellectual Property (IP) or Intellectual Property
Rights (IPR)
Laws granting legal monopoly protection to those
who create ideas or knowledge. 
biodiversity
All living organisms, their genetic material and the
ecosystems of which they are a part. 
microorganisms
Tiny living organisms, only visible with a
m i c roscope, that include algae, bacteria, fungi 
and one-celled animals. 
Ill fares the land, to hast’ning ills a prey,
Where wealth accumulates and men decay...
– Oliver Goldsmith, The Deserted Village, 1770
beings) is gaining in economic significance. The control of the remain-
ing diversity has both ethical and economic dimensions.
We are losing 1% of the rain forest every year, 2% of our cereal crop
diversity and 5% of our diversity in livestock breeds. Seventy percent 
of the coral reefs will be gone before the middle of the next century.
Between a fifth and a half of all the rural cultures being practiced today
will be extinct within another generation. Four fifths of the earth’s bio-
logical resources or bioresources are found in the lands and waters of the
South. The cash-poor but gene-rich tropical and sub-tropical regions of
the world harbour a vast (if declining) cornucopia of living org a n i s m s
in unique ecosystems ranging from rain forests to range lands to coral
reefs. Within these ecosystems lie possible solutions to food security,
livestock fertility, human senility, industrial lubricants, and textile dyes. 
Finding the economically-important genetic combinations among tens 
of millions of species can be a daunting and expensive proposition. T h e
c o s t - e fficient route to biological resources, therefore, is to tap the knowl-
edge of the farming and indigenous communities whose genius has 
nurtured and developed bioresources for hundreds of generations. 
I n d u s t r y ’s dependence upon the knowledge and advice of rural and
farming communities is a source of considerable discomfort to corpora-
tions and Northern governments. Dependence implies debt and benefit -
sharing. It is more convenient to promote the assumption that the most
valuable biodiversity remains undiscovered and wild. 
But, the biological resources of the South are seldom wild, unstudied,
unmanaged or even unimproved. The people who live with and depend
upon biodiversity for their survival know it well and are the best (often,
the only) means to developing these resources for wider uses.
Enclosing Minds
The South’s farmers were the first to domesticate almost all of the world’s
major crop and livestock species. Farmers shared and adapted these
species across millions of micro-environments long before the 20th century
era of so-called “scientific” breeding. In a world where agriculture is
becoming monoculture and farmers’ fields take on the appearance of fac-
tory production lines, it is only in the centres of genetic diversity of the
South that fields retain the genetic diversity critical to global food security.
The accumulated and intimate understanding of farming communities, not
just of individual species but of the complex inter-relationships between
species and the wider ecosystem, makes their knowledge invaluable. 
American cabinet officials estimate that the annual value of the South’s
germplasm contribution to two leading US crops was at least US$10.2
b i l l i o n .1 Flows of crop genes from farmers’ fields in the South to other
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farmers in the North, mainly via cooperative international agricultural
research programmes, is estimated conservatively at US$5 billion per
year.2 Many Northern scientists acknowledge that some major food crops
in industrialized countries would disappear altogether were it not for
regular infusions of crop genes from the South.
Recognition of the contribution of the South’s farmers to the North’s
food security is coming almost too late. A century that began with
almost all of human society living in rural areas will end with almost
half of us living in cities. Of those still on the land, at least half have
been forced to surrender their local ecological and technological under-
standing of agriculture and biodiversity for an externally-controlled sys-
tem of industrial agriculture. As farming societies lose their language
and culture, so goes their agriculture. Surely, it is long past time to con-
serve not just the planet’s bioresources but also the ecotechnologies of
its rural communities. 
Enclosing Life
The economic force behind the new act of enclosure is the biotechnology
industry, a conglomeration led by pharmaceutical and specialty chemical
companies with markets ranging from seeds and pesticides to drugs and
plastics. It is also known as the “genetics supply” industry. More accu-
r a t e l y, however, it should be known as the life industry, consisting of 
a relatively few, multi-billion dollar enterprises which use bioresources
and processes for commercial purposes. 
With the advent of new genetic technologies, the structure of industry
has changed dramatically. Though mergers, acquisitions and product
diversification are hardly new strategies for corporate concentration,
biotechnology has brought a new dimension to standard market monop-
oly practices. Genes or bioresources, whether from fields or fungi, can
be engineered and adapted to a wide range of end-uses, including agri-
cultural, pharmaceutical, or food processing products. Corporations have
become biopirates in search of biological treasures found only through
the road maps in the minds of farming communities. 
With the new enclosure of life by the intellectual property system, the
industrialized world is effectively cutting out these Southern contributors
of seeds and expertise from commercial benefit, by granting its own
inventors or breeders an intellectual property monopoly over plant and
animal varieties.
Rural communities have contributed massively to the global pharmaceu-
tical industry. In 1990, for example, about one quarter of the world’s
pharmaceuticals were derived from plants, with an annual sales value of
US$43 billion.3 About three-quarters of these drugs, with an estimated
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centres of genetic diversity
Locations where the world’s food crops are found
to have the greatest genetic diversity.
germplasm
The total genetic variability, represented by germ
cells or seeds, available to a particular population
of organisms.
life industry
Multi-million dollar industry comprised of
enterprises that use biological resources 
and processes for commercial purposes. 
biopirates
Those who use intellectual property rights to
legitimize the exclusive ownership, appropriation
and control of biological resources and knowledge. 
yearly sales value of US$32 billion, were “discovered” by pharmaceuti-
cal corporations because of their prior use in indigenous medicine. Ye t
traditional healers and indigenous communities have seldom been recog-
nized or compensated, despite their ongoing contribution to science and
i n d u s t r y. 
The proportion of the pharmaceutical trade that is plant-derived is predicted
to grow. One quarter of the 500 million medical prescriptions written each
year in the US involves a pharmaceutical derived from a leafy plant. The
sales value of these prescriptions in 1990 was estimated to be US$11 billion
a year.4 Until recently, it was not permissible in many industrialized
countries to patent drugs that were important to human well-being. In
the new era of enclosure, all industrialized countries now allow patents
on pharmaceuticals. 
With the growth of biotechnology, industry and scientists are using intel-
lectual property to gain monopoly control over biological resources and
the knowledge of farming communities from the South for 17 to 25 years.
This is biopiracy. For farmers and farming communities it may mean
having to pay for the products of their own genius. It will certainly 
mean they go unrewarded for their contribution to corporate profit s .
Enclosing Strategies
That biodiversity is declining, that corporations are becoming more 
concentrated, or even that the South’s bioresources are being pirated, 
is something less than news. That something as esoteric as intellectual
property plays a significant role in all this is probably more of a surprise. 
Intellectual property encompasses a group of laws that were intended to
protect inventors and artists from losing control over their intellectual
creations, such as sewing machines, books, or pottery designs. Everyone
from Galileo to Pasteur and Picasso has used intellectual property to
make sure that others didn’t steal their inventions or creations. The theory
is that intellectual property laws give inventors and investors confid e n c e
that their work will be rewarded and not pirated. Without that assurance,
I P supporters argue, inventors wouldn’t invent and investors wouldn’t
put up the research funds they need. 
Over time, intellectual property regimes have grown into mechanisms
that allow corporations, not individual inventors, to protect markets rather
than ideas. Rather than ensuring that inventors have an opportunity for
reward, IP provisions now grant exclusive monopolies that are scale-
biased to allow major enterprises to trade technologies among themselves
and keep smaller enterprises out of the marketplace altogether.
The protection of knowledge is not unique to Europeans. Specialization
of knowledge, and rules governing access to certain types of knowledge,
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The 6 basic forms of
intellectual pro p e rt y
• Patents




• Trade secrets 
In recent years, these six types have seen a
number of variations, designed to cover such
things as microorganisms, computer circuitry
and computer programmes. All operate by
exclusion. They give a monopoly to the owner
of intellectual property, who is granted the legal
right to exclude others from making or using
the protected creation without perm i s s i o n .
Patents and plant breeders’ rights are the two
forms of intellectual property most relevant to
living organisms.
are found in virtually all societies. But patent laws are a European
invention of the 19th century, and were designed to defend the factory
machinery of the agricultural and industrial revolutions. Intellectual
property laws were not intended to allow monopolies over the products
and processes of life. Most national laws in Europe went to great lengths
to exclude IP over living materials, foods or medicines. Yet in the past
few decades it has become increasingly common for intellectual property
to be granted in all of these prohibited areas. 
This has happened in two ways:
• Plant breeders’ rights (also known as “plant variety protection” laws)
were introduced in most industrialized countries in the 1960s and
1970s. These laws granted legal monopolies (more limited than
patents) to those who developed new varieties of plants such as 
wheat or bean varieties. 
• Beginning in 1980, court decisions in the United States opened the
floodgates to the patenting of all living organisms, including plants,
animals, genes, microorganisms and even human genetic material. 
Owning intellectual property over living things is not like owning indi-
vidual cows or fruit trees, a vegetable garden, a rice harvest, or a fish
pond. It is a different and more far-reaching form of ownership. The 
distinction can be likened to the difference between owning a bucket (or
lake) full of water, and owning the chemical formula for water. A p a t e n t
holder for water’s chemical formula would have the right not only to
decide who could have access to a particular lake, but to any water any-
where, and to the use of the chemical formula for any purpose. 
When someone has intellectual property rights over a new wheat variety,
for instance, anyone else who grows it must pay a royalty to the intellec-
tual property holder. In fact, it is more and more possible for IP h o l d e r s
to prohibit farmers from saving seed for the next year’s planting or to
exchange seed with neighbours. Under patent laws, it is also possible 
to monopolize the parts of a plant or animal such as specific genes or
genetic characteristics. If someone is granted a patent on a gene that
determines an inherited plant or animal trait, or controls the onset of a
human disease, they acquire enormous power in the marketplace because
they set the conditions for access and sale of the patented technology.
Others must obtain a license from the intellectual property holder to use it. 
By legal sleight of hand, the inherited characteristics of living organisms,
the building blocks of life itself, are defined as intellectual property. They
are protected by monopoly rights and traded as commodities in the global
market place. In recent years, in fact, intellectual property has become a
trade and environment issue in international treaties.
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patent
A form of intellectual property law that legally
recognizes a product as novel, useful and 
“non-obvious”. 
plant breeders’ rights
A form of intellectual property law that legally
grants a plant breeders’ certificate to those who
develop new plant varieties. 
Enclosing Global Conventions
Until very recently, intellectual property was subject only to national
legislation. In the mid-1990s, however, it became an international oblig-
ation. After eight years of heated negotiation, 1994 saw the conclusion
of the Uruguay Round of the General A g reement on Ta r i ffs and Tr a d e
( G AT T ) and the creation of the World Trade Organization (WTO )
which came into being in January 1995 to administer the multilateral
accord. By January 1996, the W TO had 115 member states, most of
them from the South. 
For the first time in history, the W TO / G AT T agreement includes a little-
known section on Trade-Related Aspects of Intellectual Pro p e rt y
( T R I P S ) , which represents the globalization of the intellectual enclosure
system. The powerful W TO now obligates signatories who don’t already
have such legislation to adopt intellectual property laws for plant varieties
and microorganisms. Many have observed that this is an assault on
national sovereignty, in an area historically left to national discretion.
Until TRIPS, all nations were free to determine whether and how they
would recognize intellectual property. 
Most developing countries, and some European states, had chosen not to
permit patents on food, pharmaceuticals, or other human essentials. T h e
new accord fundamentally undermines this sovereign right. The effect of
this imposition will be to legalize and facilitate the North’s appropriation
of resources and knowledge from the South. Over 99% of all patents and
plant breeders’ c e r t i ficates on living organisms are held in the North.
Under TRIPS, the only intellectual property in the world that is not 
protected is the genius of farming and other rural societies. The W TO
legitimates the piracy of community innovations on a global scale.
Not long before the W TO deal was signed, the Biodiversity Convention
came into force, following its adoption in 1992 at the UN Conference on
Environment and Development (UNCED or Earth Summit) in Rio de
Janeiro, Brazil. The convention is a legally binding document that had
been ratified by 128 governments as of October 1995. It makes several
references to the conservation of indigenous knowledge in rural societies,
and to the critical role that farmers can play in nurturing biodiversity. T h e
Convention also includes clauses endorsing intellectual property over l i f e
forms. Yet neither protection of farming communities’knowledge nor the
implications of the Convention’s intellectual property clauses have been
fully spelled out by signatories to the agreement. 
The Convention, like the WTO, facilitates the expropriation of biological
resources and knowledge from the South, especially in its articles on
access to genetic resources and technology transfer. It encourages one-
to-one, bilateral arrangements between those (mostly corporations) who
want access to resources and knowledge, and governments which are
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General Agreement on Tariffs and Trades (GATT)
International negotiating forum, founded in 1947,
for industrialized nations to regulate trade and
tariff arrangements. 
World Trade Organization (WTO)
International body which came into being on
January 1st, 1995 to monitor GATT agreements
and pursue global trade objectives. 
Trade-Related Aspects of Intellectual Property
(TRIPS)
GATT/WTO agreement negotiated in 1994 that
requires member nations to conform to industrial
country standards of intellectual property and sets
down minimum requirements for intellectual
property coverage of living organisms. 
Convention on Biological Diversity or
Biodiversity Convention
Legally-binding international agreement for
conservation and sustainable use of biodiversity
which came into force in December 1994. 
bioprospectors
Companies and individuals who explore, extract
and screen genetic diversity and indigenous
peoples’ knowledge for commercially-viable
genetic resources. 
deemed to have sovereign control over the resources that corporations
may want. Yet the Convention proposes no binding multilateral para
meters or internationally-accepted code of conduct for such negotia
tions. Tr a g i c a l l y, while granting sovereignty to governments over the
indigenous knowledge and the resources of rural societies, the Conven-
tion fails to spell out any protection for community innovation systems.
Farming communities risk being played off against one another by 
corporate b i o p rospectors and even by their own governments. Review-
ing the Biodiversity Convention, a Ciba-Geigy (now Novartis) off i c i a l
wrote that the agreement could be interpreted to do a better job protect-
ing intellectual property than the W TO .5
The W TO and the Biodiversity Convention could amount to a pincer
movement, threatening the genius and genetic resources of farming com-
munities. But the pincer is by no means closed. The Convention is now
engaged in a multi-year process of negotiation over its approach to
indigenous knowledge and intellectual property. The W TO will review
its intellectual property chapter in 1999. No developing country is obliged
to adopt IP legislation consistent with TRIPS until at least the year 2000.
“Least-developed” countries (a term not yet defined by the W TO) have




Read this chapter to get more details about how
Western intellectual property systems evolved,
and the operation of the present intern a t i o n a l
i n f r a s t ru c t u re of intellectual pro p e rt y. Key 
i n f o rmation includes
• a brief history of European patent laws and
intellectual property systems
• the rationale behind the patent monopoly
system in industrialized countries
• an overview of the key influences and 
agreements in the present global intellectual
property system
• the issues at stake regarding access and
c o n t rol to knowledge under existing IP
agreements.
Refer to Appendix A: A Short History of the
Patent System and Appendix B: Who Has
Access to We s t e rn Intellectual Pro p e rt y
Systems? for more information on the develop-
ment of intellectual property systems over time. 
Chapter 2I
A Ve ry Civil Monopoly…
The royal prerogative to grant monopolies is as old as written history.
Cooks were granted one year monopolies over new recipes in the seventh
century B.C. Monopolies over fishing and textiles were not unusual in
ancient Rome. The Dutch and the Venetians granted competing patents
for telescopes in the days of Galileo. Seventeenth century England
employed a whole range of monopolies, including the charters granted
to regional trading companies (the British East India Company and the
H u d s o n ’s Bay Company, for example) and specific monopolies for mechan-
ical inventions. Whether the monopolies were for trade or for inventions,
the logic was the same: high-risk and high-cost work deserved special
protection and rewards. If Eli Whitney took the time and trouble to invent
a cotton gin, it was not fair that someone else could come along, copy
the machine, and reap the rewards, having contributed nothing to the
enterprise. State-imposed monopolies were seen to be an easy and
inexpensive method of encouraging innovation and ensuring benefits
for the inventor.
In fact, intellectual property, as the logical extension of private property,
seemed to be a near-perfect mechanism to stimulate scientific progress:
• By limiting the monopoly to six or a dozen years, the patent system
recognized that every invention is built upon people and ideas that have
gone before. The temporary nature of the monopoly made sure that no
one would have a permanent grip on an industry or a technology.
• The temporary monopoly encouraged secretive inventors to reveal
their inventions rather than keeping them as trade secrets. To be
patented, an invention had to be adequately described so that someone
else could replicate the same idea. The actual invention had to be made
publicly available for others to study and possibly improve upon. 
• The monopoly would be useless unless it was commercialized. Patents
did not guarantee wealth, they only ensured that an economically-
useful invention, bought or used in a commercial context, would
return profits to the inventor only. Having a patent did not mean 
having a guaranteed profit. If society did not find the invention 
helpful, the inventor would not be able to charge royalties and 
would not make money. 
• Patent laws were established as part of civil law, not criminal law. If
someone usurped an invention from the patent-holder, society did not
come to the rescue with the police as they would over private property
theft. The inventor would have to take the patent pirate to civil court. 
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O V E RV I E W
The world’s present intellectual prop-
erty system has its roots in 19th cen-
tury European efforts to promote sci-
e n t i fic and industrial growth. Patent
laws gave inventors monopolies that
brought economic benefits and dis-
couraged competitors. Stiff resistance
to the patent system saw patents as
a barrier to the spread of new tech-
nologies. As a compromise, European
nations agreed in 1873 to establish
compulsory licensing of patents, but
it did not last long. An international
intellectual property infrastructure
dominated by industrialized Northern
nations has evolved up to the pre-
sent day to include a range of con-
ventions and agreements governing
everything from industrial property to
plants and other life forms in both
North and South. Two recent and
very significant agreements are the
Biodiversity Convention of 1992 and
the WTO / G AT T TRIPS of 1994. T h e s e
agreements protect the biotechnology
industry and oblige signatories to
pass intellectual property l e g i s l a t i o n .
Farming communities and Southern
countries are marginalized from the
rewards and benefits of industrial intel-
lectual property systems. 
INTELLECTUAL PROPERTY MONOPOLIES
Systems of Greed
• All the costs associated with patent applications and litigation were to
be borne by the patent-holder, not by society. 
In short, by allowing inventors a brief monopoly over their own ideas,
society could encourage scientific progress at no cost to the country. 
…Leads to a Ve ry Uncivil Debate
For many, proof of the efficiency of the patent system lay in Britain.
During the agricultural and industrial revolutions of the 18th and 19th
centuries, Britain led Europe in technological development. A l t h o u g h
France was acknowledged as the center of science and Germany was
credited with many scientific principles of commercial application,
Britain was the country that carried ideas into practice and won 
the commercial rewards. Struggling to find a reason for this, many
Europeans concluded that it was the incentive provided by British 
patent laws. Technological historians doubt that this was so. 
During the period of intense social upheaval that plagued continental
Europe into the middle of the 19th century, including the French
Revolution and the Napoleonic Wars, scientific progress in Great Britain
leapt ahead. British industry was spared most of this unrest, so while the
cream of French and German science marched either into war or up the
steps to the guillotine, their English counterparts carried on. Yet some of
the most important inventions of the period were never patented or were
the result of British government competitions in which successful inven-
tors were guaranteed a flat payment for devising a specific problem-
solving innovation. 
European governments followed the lead of revolutionary governments
in France and the United States and adopted their own variations of the
British patent system during the first half of the 19th century. By mid-
c e n t u r y, however, many scientists, industries and countries began to
have their doubts. Patents seemed to give technology leaders more 
market advantage than anticipated. It was hard for others to catch up. 
In general, technology-importing countries saw little reason to adopt
patent laws that would force them to export royalties to other countries.
Technology exporters, on the other hand, were anxious to take out patents
in every country that offered a market. Even the United States, which
had entrenched patents in its constitution, was reluctant to recognize 
foreign patents since it too needed cheap access to British technology 
in order to develop. 
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…But times are alter’d, trade’s unfeeling train
Usurp the land and dispossess the swain…
– Oliver Goldsmith, The Deserted Village, 1770
Refer to Appendix A for a summary of how the
patent system has evolved through time,
including highlights of some of the precedent-
setting incursions of intellectual property laws
into plant, animal, microbial and now human life.
Between 1850 and the early 1870s, technology importers in Switzerland
and Germany ardently resisted every move to impose patent laws in
their countries. The Dutch and even the British moved to reduce the
patent monopoly, and parliamentary debates were vociferous in accusing
patent monopolies of being barriers to progress. 
Why the uproar? First, proving ownership over intellectual property or
over ideas was no easy matter. Inevitably, disputes led to legal costs and
legal costs meant that the individual (or company) with the deepest
pockets had the best chance of winning in the courts. The vast gray area
between a genuinely new idea and one which was just a minor variation
on an old idea gave room for endless legal wrangling. Second, and more
important, patents did not (as the public assumed) merely allow inventors
to obtain royalties on their ideas. They established inventors’rights to use
exclusive monopoly to set the conditions of sale for their inventions. 
Exclusive monopoly allowed patent-holders to determine who would
have access to technology and under what (often varying) conditions.
This meant that a patent-holder, almost invariably a company, could vary
the licensing cost to customers in return for certain non-cash favours 
or advantages. The inventor could even deny access to some customers
regardless of their off e r. Thus, companies could use the patent system 
to keep other companies or countries out of certain markets. 
For the newly industrializing countries of Europe and North America 
in the 19th century, the patent system was clearly a barrier to new tech-
nologies and trade opportunities. Technology-dependent German compa-
nies found it hard to obtain British inventions at reasonable prices. Later,
when Germany caught up to Great Britain, Swiss chemical and textile
manufacturers complained that German technologies were inaccessible
when patents were involved. By and large, American enterprises ignored
European patents and took whatever technologies their economy required,
while at the same time being sure to patent their home-grown discoveries.
The Great Capitulation
With patent-holders on the defensive, governments and industry met at
the 1873 Wo r l d ’s Fair in Vienna to resolve their differences. Industry
proposed to accept c o m p u l s o ry licensing to make technologies avail-
able at equitable prices if competitors could prove that patents were not
being “worked” to the benefit of society or were not accessible at prices
that were reasonable.
Countries and companies initially opposed to the patent system assumed
that compulsory licensing would ensure that patents would be available
as public interest dictated. Over the ensuing quarter-century, governments





Legal linguistics aside, you can get a patent in
most countries if your invention is:
• new (or can claim “absolute world novelty”)
• non-obvious (that is, includes a real 
inventive step)
• useful (has commercial application).
In return for depositing a sample of the patent-
ed product or process and describing it so that
others skilled in the art can do the same thing,
inventors get the right to:
• exclusive monopoly over the invention for
17 to 25 years
• royalties (a surcharge above the normal sale
price) on the use of their invention
• control access and set the conditions for the
sale of the invention, meaning the right to
deny or vary costs depending on the cus-
tomer and the market conditions.
Under normal monopoly practices, patent-
holders have the right to determine the price
(and royalty rate) for access to their invention.
Everyone who can pay can use the invention.
This ensures that the inventor can obtain a
return on the investment involved in developing
the invention, if customers are interested.
C u rrent patent regimes, however, allow for
exclusive monopolies, meaning that patent-
holders may arbitrarily set the conditions for
access to their inventions. Patent-holders can
set different conditions (price and other market
considerations) for diff e rent companies and
exclude some buyers outright. A life industry,
for example, could license another company to
use its pesticides in Asia, in return for the other
firm’s plant varieties in Latin America or its
pharmaceuticals in Africa. New or smaller com-
panies that don’t have the market or industry
breadth of the bigger firms can’t make deals like
that. Patents, there f o re, are scale-biased in
favour of multinationals.
protection. Those who had revoked patent laws re-instituted them, and
the world looked forward to an era of unparalleled technological progress. 
The Campaign to Patent Life
The late 20th century has seen further patent system developments
around the patenting of life forms that are products of biotechnology 
and industrial manipulation of genetic materials. 
• In 1980, the US Supreme Court ruled in the landmark case of
Diamond v. Chakrabart y that genetically engineered microorg a n i s m s
are patentable.
• In 1985, the US Patent and Trademark Office ruled that plants 
(previously protected by plant breeders rights) could qualify under
industrial patent laws.
• In 1987, the US Patent and Trademark Office ruled that animals 
are patentable.
As a result of these decisions, virtually all living organisms in the United
States, including human genetic material, became patentable subject
m a t t e r, just like any other industrial invention. As one industry analyst
explained: “Since 1980 it can no longer be said that something is not
patentable just because it is living… (B)iotechnology has advanced so
rapidly in recent years that there is now virtually no life form which
does not have … potential as the subject of patent application.”7
For the life industries that use sophisticated biotechnology techniques,
living organisms and knowledge about their uses have become prized
commodities. Companies seek to control them by claiming intellectual
property rights. In the United States alone, biotechnology patent applica-
tions increased by more than 74% from 1988 to 1993. According to 
D r. Alan Goldhammer of the American-based Biotechnology Industry
O rganization, total product sales for the US biotechnology industry 
rose from US$4 billion in 1991 to an estimated US$7 billion in 1994.8
Similar trends were seen in other industrialized countries.
Biotechnology is a global industry, and intellectual property has become
big business. Intellectual property laws in one country are of limited
value to corporations without parallel recognition in others. T h a t ’s why
the US and other industrialized nations have lobbied aggressively in
recent years for international harmonization of intellectual property 
legislation. With a global reach, intellectual property laws give trans-
national corporations extraordinary economic control in new markets,




A legal mechanism that obliges patent holders to
make their inventions available at equitable prices. 
Taking the Patent Cure
A re patent monopolies an efficient way for society
to encourage beneficial research? According to
the US Office of Technology Assessment (OTA),
American pharmaceutical companies (in 1990
dollars) spent an average of US$194 million
bringing new patented drugs to market in t h e
1980s. Is it worth it? Not according to re s e a rc h e r
Anita Kunz: “Of the 348 drugs introduced by the
25 largest pharmaceutical companies between
1981 and 1988, only 12 (or 3 percent) were
deemed important therapeutic advances by the
[US Food and Drug Administration].” The vast
majority (97%) off e red little or no tre a t m e n t
advance. Sick Americans paid US$67 billion
for this in 1990. Approximately one-fifth of this
payment was in the form of patent royalties. The
exact cost of monopoly pricing made possible
by patents is a larger, but uncertain, figure. 6
The US pharmaceutical industry stands even
less ennobled when one considers a govern-
ment re p o rt that 70% of the useful new dru g s
w e re based on government funding and/or
public sector re s e a rch, even though the patents
w e re acquired by private companies. 
We re most new American drugs simply useless,
we might have cause to complain, but not t o
panic. As drug prices soared at four times the
rate of inflation in the early 1990s, the US
General Accounting Office revealed that more
than half of all new drugs have serious, even
l i f e - t h reatening, risks, even after US govern m e n t
a p p roval. Could not society find a less expensive
and dangerous way to develop new dru g s ?
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A free market mechanism that allows private enterprise to develop and introduce new technologies and ideas
with the aid of a temporary monopoly that costs taxpayers nothing.
The right of inventors to protect their inventions and to benefit from them is a traditional human right recognized
under the Universal Declaration of Human Rights. 
IP Systems afford equal protection to individual inventors and multinational corporations. If a single inventor
working in her home develops a patentable idea, she can force even the largest corporations to honour her patent
and pay royalties for its use.
Inventors produce ideas that can easily be copied by others who have contributed neither time nor money to
their development. Unless inventors have intellectual property protection, they have little hope of recouping their
investment costs or of profiting from their work. 
Inventors have a temporary monopoly only for the 17 to 30 year period in which they pay registration fees for
their discovery in most countries. The temporary nature of the monopoly acknowledges that the invention is
based upon other ideas that have gone before. When the protection period expires, the invention is free to 
anyone who wishes to use it. 
Given the enormous research investment in fields like micro-electronics and biotechnology, inventors must be
able to obtain royalties and be free to set the conditions under which others will have access to their ideas.
Patents are equally available to individuals and large corporations with patentable ideas. Independent patent
offices adjudicate disputes under the rule of national law.
Without the opportunity to protect ideas, we would not have biotechnology, new pharmaceuticals, chemical 
agricultural inputs or advances in computers, communications and transportation.
Why would anyone invest in an idea if the idea could immediately be taken and exploited by others?
Patents encourage technology diffusion by: (1) requiring the inventor to fully disclose the patent so that another
skilled person can reproduce the same invention; (2) ensuring the idea will be freely available to everyone when
the patent expires; (3) giving the inventor confidence that the idea can be released in the marketplace without
losing benefit.
If creative people can expect to reap the benefits of their inventions and if they find favour in the marketplace,
they will be more inclined to invent.
Companies cannot live off one another ’s research, so they are encouraged to undertake their own research and
improve on products and processes in the marketplace. This stimulates competition and benefits society.
Because patents encourage investor and inventor confidence, they are more likely to take risks and explore
unorthodox areas of research. In some fields, companies are likely to diversify their research activities.
What is intellectual property?
Is IP a matter of human rights?
Who are the inventors?
Does investment need protection?
Why a monopoly?
Why exclusive monopoly?
Is the IP system scale-biased?
Do patents encourage innovation?
Do patents encourage re s e a rch investment?
Do patents encourage dissemination of
technology?
Do patents encourage more inventors?
Do patents encourage competition?
Do patents encourage diversification?
TABLE 1
The Debate over Intellectual Property Monopolies
IN FAVOURISSUE
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An artificial monopoly created by the State on behalf of private interests that allows industry to withhold ideas and charge monopoly prices
for the ideas they make available.
Recognizing that every inventor and invention stands upon the shoulders of those who have gone before, society’s right to inventions 
supersedes the rights of the inventor. The right to imitate is entrenched in the Universal Declaration of Human Rights.
Over 95% of all patents are held by large companies or government institutions.
Today’s inventors work for corporations who use inventions to increase their production, efficiency or market access, and they receive an
immediate and direct benefit from their investment as a result. The owner of a new invention usually has a two to three year lead time in the
marketplace in which to establish her or his identity before competitors can copy the idea, so there is no need for monopoly.
There are many tricks that corporations use to extend the life of a patent, whether through placing the primary invention within a patent 
“family” and/or by adding supplementary patents on products or processes. Even a 20-year patent on a new technology can “cap” the knowledge
that has gone before and lead to market domination for generations to come.
A fair return on investment can be achieved by setting a standard royalty rate for anyone seeking access to an invention. To allow companies
to set the conditions and costs for access means that IP can be used as a non-tariff trade barrier against smaller firms or poorer regions.
There is no economic reason for exclusive monopoly.
The average cost of a patent application in the United States is more than US$10,000 and the average cost of patent litigation is more than
US$250,000. Patent power goes to the companies with the deepest pockets and the largest stable of lawyers.
Government studies in Canada, the United States and the UK have independently concluded that there is no evidence the patent system
encourages innovation. There are no statistics to support the contention that granting exclusive monopolies encourages innovation. Reason
suggests that monopolies, by their very nature, encourage complacency and discourage risk-taking.
T h e re is no empirical evidence to correlate re s e a rch activity with private investment. In industrialized countries, patents encourage the transfer
of public sector research funds, personnel, and inventions to the private sector, so that society tends to pay twice, once for the basic research
through tax dollars, and then for the applied research through royalties and monopoly pricing.
Throughout history, technology-importing countries (including the US and Switzerland) have opposed patents as a barrier to their access to
technologies necessary for development. Only when countries become technology exporters do they favour patents.
Almost all the world’s patents are granted to corporations not individuals. Statistics on the number of individual inventors are scarce, but 
in the case of the US Plant Patent Act, the ratio of plant breeders to the general population has declined steadily since the legislation was 
introduced 65 years ago.**
Rather than developing new ideas, most corporations spend money trying to “invent around” a competitor’s idea. In agriculture, this approach
is known as “chrome and tailfin” plant breeding, in which breeders make a minor alteration to an existing variety and then stake their own
patent claim. Big companies can overwhelm the patents of little companies or single inventors. 
No empirical data exist to show that patents encourage diversification. In American agriculture, the record of both the Plant Patent Act and
the Plant Variety Protection Act indicates that corporate breeders concentrate on the high-value, established markets and do not move into
high risk areas. Patents are used to consolidate old markets, not to create new ones.
**RAFI Communiqué, “Sixty Five Years of the US Plant Patent Act (PPA)”, November/December 1995. 
IN OPPOSITION
For example, in India over 70% of pesticides are applied to cotton and
rice. The Indian government is hoping to develop a genetically engineered
cotton that will be resistant to the cotton bollworm. They want to develop
a cotton variety containing the insect-resistant Bt toxin gene. Bt or
Bacillus thuringiensis is the most widely-used source of natural insect
resistance in the research and development of t r a n s g e n i c crops. Monsanto
Corporation, a giant agrochemical firm, reportedly offered to sell its
patented Bt gene to the Indian government for US$7.74 million. The cost
was too high, and the Indian government was forced to reject the deal.9
The Wo r l d ’s Intellectual Pro p e rty Infrastru c t u re
As the concepts and use of intellectual property rights and patents have
evolved, so has an international infrastructure to deal with intellectual
property concerns. IP laws are national, but countries have negotiated
international agreements which deal with various types of intellectual
p r o p e r t y. The World Intellectual Pro p e rty Organization (WIPO) is 
an international body based in Geneva that administers 20 conventions
and treaties adopted by the world community. In addition to those deal-
ing with copyright, trademarks, industrial designs, and computer circuits,
WIPO administers several international IP agreements that are now
applied to living organisms. These include two patent agreements, 
one agreement that governs the deposit of microorganisms for patent
procedure, and two for plant breeder’s rights: 
• The Paris Convention for the Protection of Industrial Pro p e rt y
(whose signatories form the Paris Union for the Protection of
Industrial Property).
• The Patent Cooperation Tre a t y.
• Two versions of the International Convention for the Protection of
New Varieties of Plants (whose signatories form the Union for t h e
P rotection of New Varieties of Plants or U P O V) which governs
plant breeders’ r i g h t s .
• The Budapest Tre a t y on the International Recognition of the Deposit
of Microorganisms for the Purposes of Patent Procedure.
Each of these agreements has been revised over time, and each has its
own list of signatories, who may or may not have signed the most recent
version of the agreement.
Despite a dominant world trend to harmonize intellectual property rights,
the European Parliament voted down legislation on March 1, 1995 aimed
at removing all barriers to life patenting in the European Union. It rejected
a proposal to introduce common standards in Europe for the patenting of
plants, animals and human genes. The issue is again before the parliament
in late 1996. 
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Patents From Plants 
to People
• There is a product and a process patent on
the agro-bacterium that fixes soil nitrogen
around the roots of one soybean variety.
• There are a half-dozen patents on specific
genes conferring yield improvement and
disease resistance in the soybean.
• There is a patent on the high-lysine charac-
teristic in the plant’s oil.
• There are patents on the inbred lines used to
create an experimental hybrid soybean.
• There is a plant breeders’ rights certificate
on the entire plant variety.
• There is a species patent on transgenic 
soybeans.
• There is a patent on the cow (and her calf)
that eat the soybean meal.
• There’s another patent on the Bovine Growth
Hormone that helps convert the plant to
milk…
• There is yet another patent on the human
cell line of the farmer…
• …and still another on DNA fragments re l a t e d
to her brain.
The Biodiversity Convention
The Convention on Biological Diversity is a multilateral agreement 
r a t i fied by 128 governments as of October 1995. When the Biodiversity
Convention was adopted by the Earth Summit in July 1992, the US made
global headline news by refusing to sign it. The American biotechnology
industry feared its activities would be constrained by the Convention’s
clauses on intellectual property. Several years later, the US remains 
conspicuous by its absence from the list of countries which have now
r a t i fied the legally binding agreement. Intellectual property rights remain
one of the most contentious issues for the Convention’s signatories. 
I r o n i c a l l y, while Northern industry fears that its right to do business is
curtailed by the Convention, many in the South believe it actually facili-
tates the appropriation of Southern biological resources and peoples’
knowledge. As one Southern biodiversity advocate observed, “The
Conference of the Parties to the Biodiversity Convention hopes to avoid
the fact that prevailing intellectual property regimes de facto pirate the
technologies of communities that have no resources to protect their
knowledge, and are fundamentally opposed to exclusive monopoly 
over life forms.”1 0
The Convention offers some leeway for “communities embodying tradi-
tional lifestyles” to negotiate protection of their knowledge and resources,
at least as they relate to biodiversity conservation. Articles regarding i n
s i t u conservation (see Glossary in Appendix D) could be invoked to
claim protection for farming communities whose lands and waters harbour
b i o d i v e r s i t y. But so far, the Convention has no teeth in this regard:
• No binding and universally-applicable code of conduct has been
established to regulate bioprospectors, and no mechanism has been
developed to control access by outsiders to farming communities’
knowledge or biological resources. Instead, contracting parties (i.e.
governments) are expected to arrive at “mutually agreed terms”
regarding access to genetic resources. This strictly bilateral approach
to access makes it likely that countries of the South will be played 
o ff against one another by wealthier, better-informed Northern inter-
ests. It leaves community knowledge-holders entirely at the mercy 
of governments. 
• No method has been established to determine an “equitable sharing”
of benefits derived from biodiversity. 
• No account has been taken of the fact that intellectual property 
rights over living things are anathema to many of the peoples whose
knowledge is the target of clauses about “communities embodying
traditional lifestyles”. 
• The Convention sets a firmly entrenched, industry-biased system of
intellectual property rights against some hypothetical protection of
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transgenic organism
Any organism that has been genetically engineered
using genes from another species, or its offspring. 
World Intellectual Property Organization (WIPO)
Organization that houses all intellectual property
conventions adopted by the world community.
Paris Convention for the Protection of Industrial
Property 
The principal intergovernmental body established
to govern the patent system and determine the
ground rules for granting of patents. 
Patent Cooperation Treaty
Treaty to create a global patent system, to ensure
that a patent granted in one country will be
adopted in all member countries. 
Union for the Protection of New Varieties of
Plants (UPOV)
International intellectual property conventions
covering plant breeders’ rights. 
Budapest Treaty
International treaty governing the deposit of
microorganisms for the purposes of patent
procedure. 
life patenting




What the Biodiversity Convention Says 
Excerpts Relevant to Intellectual Property
The “contracting parties” in the text are the 128 ratifying nations to the Convention. The sections quoted here are especially relevant to
b i o d i v e r s i t y, indigenous peoples’ knowledge, and intellectual property rights.
P R E A M B L E point 12: [Recognizes] the close and traditional dependence of many indigenous and local communities embodying 
traditional lifestyles on biological resources, and the desirability of sharing equitably benefits arising from the use of traditional 
knowledge, innovations and practices relevant to the conservation of biological diversity and the sustainable use of its components.
A RTICLE 1 O b j e c t i v e s : The objectives of this convention … are the conservation of biological diversity, the sustainable use of its 
c o m p onents and the fair and equitable sharing of benefits arising out of the utilization of genetic resources, including by appropriate access
to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over those resources and to 
technologies…
A RTICLE 2 Use of Terms, point 13: ‘In situ conservation’ means the conservation of ecosystems and natural habitats and the main-
tenance and recovery of viable populations of species in their natural surroundings and, in the case of domesticated or cultivated species,
in the surroundings where they have developed their distinctive properties.
A RTICLE 3 P r i n c i p l e : States have … the sovereign right to exploit their own resources pursuant to their own environmental policies,
and to ensure that activities within their jurisdiction or control do not cause damage to the environment of other States…
A RTICLE 8 In-situ Conservation, clause (j): Each Contracting Party shall … (j) subject to its national legislation, respect, preserve
and maintain knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for
the conservation and sustainable use of biological diversity and promote their wider application with the approval and involvement of the
holders of such knowledge, innovations and practices and encourage the equitable sharing of the benefits arising from the utilization of
such knowledge, innovations and practices.
A RTICLE 10 Sustainable Use of Components of Biological Diversity, clause (c): Each Contracting Party shall … (c) Protect and
e n c o u rage customary use of biological resources in accordance with traditional cultural practices that are compatible with conservation
and sustainable use requirements …
A RTICLE 15 Access to Genetic Resources , clauses 4, 5, 6: 4. Access, where granted, shall be on mutually agreed terms … 5. A c c e s s
to genetic resources shall be subject to prior informed consent… 6. Each Contracting Party shall endeavour to develop and carry out
s c i e n t i fic research based on genetic resources provided by other Contracting Parties with the full participation of, and where possible
in, such Contracting parties. 
A RTICLE 16 Access to and Tr a n s f e r of Te c h n o l o g y, clauses 1 and 2: 1. Each Contracting Party, recognizing that technology
includes biotechnology …undertakes … to provide and/or facilitate access for and transfer to other Contracting Parties of technologies that
are relevant to the conservation and sustainable use of biological diversity and make use of genetic resources … 2. In the case of tech-
nology subject to patents and other intellectual property rights, such access and transfer shall be provided on terms which recognize and
are consistent with adequate and effective protection of intellectual property rights …
A RTICLE 17 Exchange of Information, clauses 1 and 2: 1. The Contracting Parties shall facilitate the exchange of information … 
2. Such exchange of information shall include exchange of results of technical, scientific and socio-economic research, as well as infor-
mation on … indigenous and traditional knowledge as such and in combination with the technologies referred to in Article 16 … It shall
also include … repatriation of information.
A RTICLE 19 Handling of Biotechnology and Distribution of its Benefits, clause 2: Each Contracting Party shall … promote and
advance priority access on a fair and equitable basis by Contracting Parties … to the results and benefits arising from biotechnologies
based upon genetic resources provided by those Contracting Parties. 
indigenous knowledge-holders by governments, who themselves risk
being played off one against the other. Intellectual property rights,
which are much better suited to Northern industry than to developing
countries governments or to farming communities, will be “adequately
and effectively” protected. 
The C o n f e rence of the Parties to the Biodiversity Convention (COP)
met for the second time in Indonesia in November 1995. Intellectual
property was high on the agenda, and so was the issue of indigenous
knowledge, thanks largely to the work of non-governmental and indige-
nous peoples’ o rganizations who insisted that it be part of any discussion
of intellectual property. It was accepted at the meeting that intellectual
property should be addressed in tandem with “indigenous knowledge”,
and signatories to the Convention are slated to consider indigenous
knowledge at the third COP in Buenos Aires, A rgentina, in November
1996. They will also consider several issues relating to agricultural bio-
d i v e r s i t y. Farming communities and other rural peoples are now org a n i z-
ing to participate in these discussions, and are developing proposals to
defend Farmers’ Rights (see Chapter Four) and the rights of indigenous
knowledge holders within the Biodiversity Convention. 
The World Trade Org a n i z a t i o n
The General Agreement on Ta r i ffs and Trade (GATT) was established in
1947, and laid down the ground rules for international trade. It began as
a club of 23 industrialized countries of Europe and North America, whose
aim was to revive trade after World War Two by eliminating barriers and
“distortions” to international trade. The original GAT T a g r e ement has
been amended eight times. At the beginning of 1996, the GATT was 
subsumed by the new World Trade Organization (WTO). By the end 
of January 1996, it had grown to include 115 member states, of which
84 are developing countries by UNDP criteria. Other governments of 
the South are preparing to join.
Late in 1994, the most recent GAT T revisions were adopted with the
conclusion of the protracted Uruguay Round of negotiations (named
after the country where they began in 1986). During the Uruguay Round,
intellectual property was discussed as a trade issue in GAT T for the fir s t
time. The United States and Japan argued that the absence of intellectual
property protection in developing nations was an unfair trade barrier and
should be subject to retaliatory measures. The United States maintained
that there should be “no exclusions” to the subject matter protected under
intellectual property laws, with biotechnology products and processes
high on their agenda. Before the round was over, industrialized countries
had succeeded in having intellectual property included in GAT T, as the
TRIPS agreement on the Trade Related Aspects of Intellectual Property. 
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Conference of the Parties to the Biodiversity
Convention (COP)
All the countries that have ratified the Biodiversity
Convention. 
If there is some scope to protect farming communities’ knowledge in the
Biodiversity Convention, it is not considered in the W TO. It is clear that
all W TO members must adopt (if they have not already done so) intel-
lectual property legislation which conforms to the TRIPS provisions.
S p e c i fic a l l y, all signatories must 
• provide patent coverage for microorg a n i s m s
• have some form of intellectual property legislation to cover plants.
They may decide for themselves about intellectual property rights over
animals. Whatever people in the South may feel about patenting life
forms, it is being legislated for the world by the W TO. 
Under the W TO, all so-called developing countries, however, have at least
until the year 2000 to implement the agreement’s intellectual property
clauses. Countries categorized as “least developed” have until 2004. In
1999, the World Trade Organization will review the new intellectual
property provisions. Significant changes to the agreement could be
achieved because of the five to ten year grace period, including changes
that could benefit farming communities. 
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TABLE 3
South Members of the World Trade Organization
Using UNDP definitions of developing and least developed countries, the table lists all WTO members as of January
1996 who are likely to fall into the category of developing or least developed. Least developed are highlighted in
bold.
Antigua and Barbuda, Argentina, Bahrain, Bangladesh, Barbados, Belize, Bolivia, Botswana, Brazil, Brunei Darussalem, B u r k i n a
Faso, Burundi, C a m e roon, Central African Republic, Chile, Colombia, Costa Rica, Côte d’Ivoire, Cuba, Cyprus, D j i b o u t i ,
Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Gabon, Ghana, Guatemala, Guinea, Guinea Bissau, Guyana, H a i t i ,
Honduras, Hong Kong, India, Indonesia, Jamaica, Kenya, Korea, Kuwait, Lesotho, M a d a g a s c a r, Malawi, Malaysia, M a l d i v e s ,
Mali, Mauritania, M a u r i t i u s , Mexico, Morocco, Mozambique, Myanmar, Namibia, Netherlands (and Netherlands Antilles),
Nicaragua, Nigeria, Pakistan, Paraguay, P e ru, Philippines, Qatar, Romania, Saint Lucia, St. Vincent and the Gre n a d i n e s ,
Senegal, S i e rra Leone, S i n g a p o re, South Africa, Sri Lanka, Surinam, Swaziland, Tanzania, Thailand, Togo, Trinidad and To b a g o ,
Tunisia, Tu r k e y, Uganda, U ru g u a y, Venezuela, Zambia, Z i m b a b w e
Sources: WTO data, Canadian Department of Foreign Affairs, UNDP Human Development Report
Refer to Appendix B for a comparison by poten-
tial users of access to Western intellectual prop-
erty systems. It illustrates how the current sys-
tem of intellectual property favours industry,
while leaving public sector institutions and rural
communities unable to compete. 
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TABLE 4
GATT TRIPs: Relevant Clauses
Section 5: Patents 
A rticle 27 Patentable Subject Matter
1. … [P]atents shall be available for any inventions, whether products or processes, in all fields of
t e c h n o l o g y, provided they are new, involve an inventive step and are capable of industrial application.
… [P]atents shall be available and patent rights enjoyable without discrimination as to the place of
invention, the field of technology and whether products are imported or locally produced. 
2. Members may exclude from patentability inventions … to protect order public or morality, including
to protect human, animal or plant life or health or to avoid serious prejudice to the environment, 
p rovided that the exclusion is not made merely because the exploitation is prohibited by their law.
3. Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals;
(b) plants and animals other than micro - o rganisms, and essentially biological processes for the 
p roduction of plants or animals other than non-biological and microbiological processes. However,
members shall provide for the protection of plant varieties either by patents or by an effective s u i
g e n e r i s system or by any combination thereof. The provisions of this paragraph shall be re v i e w e d
four years after the date of entry into force of the WTO Agre e m e n t .
A rticle 65 Transitional Agre e m e n t s
1. … [N]o Member shall be obliged to apply the provisions of this Agreement before the expiry of a
general period of one year following the date of entry into force of the WTO Agre e m e n t .
2. A developing country Member is entitled to delay for a further period of four years the date of 
application …
4. To the extent that a developing country Member is obliged by this Agreement to extend pro d u c t
patent protection to areas of technology not so protectable in its terr i t o ry on the general date of 
application of this Agreement for that Member … it may delay the application of provisions on 
p roduct patents … to such areas of technology for an additional period of five years.
A rticle 66 Least-Developed Country Members
1. In view of the special needs and re q u i rements of least-developed country Members … such
Members shall not be re q u i red to apply the provisions of this Agreement … for a period of 10 years
f rom the date of application … The Council for TRIPs shall, upon duly motivated request by a 
least-developed country Member, accord extensions of this period.
24
25
Read this chapter to get an overview of alterna-
tive perspectives to the Western intellectual
property system, including
• how Western intellectual property systems
d i ffer from non-industrial or indigenous 
systems
• the challenges faced by non-industrial soci-
eties in defending their right to collectively
use and nurture their knowledge of biological
resources
• the key role of Southern farmer innovators in
preserving and using global biodiversity
• case studies of how systems of generosity
are being threatened by present intellectual
property trends.
Refer to Appendix C: Biopiracy and
Bioprospecting Activities for information on
many of the corporations and research institutes
that are tapping indigenous knowledge in their




The Logic of Genero s i t y
Rural societies differ greatly from one another in their views of knowl-
edge-sharing and their approaches to innovation. Concepts of property,
land, and nature also vary. Many communities look upon most property
as communal. Others confer personal or family custodianship over land
and living resources. It is not unusual for agricultural communities to
permit de facto ownership over crops and livestock, including the suc-
ceeding generations of domesticated species. It is unheard of, however,
for non-industrial farming communities to grant unlimited rights to land
and resources, or to permit ownership of the processes of life. Concepts
like stewardship or custodianship come much closer to rural realities
than those such as exclusive monopoly, private property, or intellectual
p r o p e r t y.11
In most rural societies, knowledge and innovation are not seen as com-
modities but as community creations handed on from past to future gen-
erations. The earth and nature are used and managed but are not exclu-
sively owned. In contrast, European-based intellectual property rights
are founded on the belief that innovative ideas and products of human
genius can be legally protected as private property. Plant breeders’ r i g h t s
and recent applications of patent law further assert that a vast array of
living things are also products of human genius, subject to private
monopoly controls. 
There is logic to rural systems of generosity. Farmers understand that
they must experiment and that new genetic combinations must be intro-
duced into their fields in order to compete with diseases and pests. T h e
freer the exchange, the greater the potential benefit. This simple truth
has been lost in the industrialized countries where intellectual property
has created secrecy and reduced scientific exchange.
Every society is complex and farming communities manage extraordi-
narily complex ecosystems. It is not surprising that knowledge special-
ization and apprenticeship systems are common, and that reward mecha-
nisms ensure that knowledge is preserved, shared and enhanced. Patent
lawyers like to compare these customary practices to the medieval
European guild system that gave rise to intellectual property laws in the
North. Although the comparison is fair, neither today’s farming commu-
nities nor yesterday’s guild members would recognize the intellectual
property regimes being imposed by the World Trade Organization. 
O V E RV I E W
Western concepts of intellectual
property differ radically from most
rural and indigenous systems of
knowledge and innovation. Most
non-industrial societies see knowl-
edge and innovation as a collective
creation to be held in trust for future
generations. This perspective is in
direct contrast to industrial intellectu-
al property systems that view natural
resources, genetic materials and
knowledge as commodities. When
traditional systems of generosity are
confronted with the new enclosure
system, they face the challenge of
preserving the integrity of their com-
munity knowledge despite mounting




Common Thre a d s
All peoples have laws, customs and well-defined practices to regulate
land ownership, land and resource use, and the acquisition of diff e r e n t
types of knowledge. Yet within the vast cultural diversity of farming
communities, there are striking common threads which unite them and
distinguish their view of nature and innovation from the values and
world view that are enshrined as law in industrial societies. Some of
these are especially relevant to the intellectual property debate. 
• Knowledge and innovation cannot be isolated from land and culture.
“[When we talk about biodiversity] we are really talking about our
whole world view, our cultures, our lands, our spirituality… These
a re all linked.” (Stella Tamang, Federation of Nationalities, Nepal)1 2
For farming communities and for all rural peoples, their relationship
to land is an important part of their identity. The lands and waters
they live with underpin who they are and are the foundation of their
very survival. Over and over again, when reflecting on biodiversity 
or indigenous knowledge, rural people insist that living things cannot
be understood separately from the land that nurtures them. Peoples’
myriad uses of natural resources cannot be separated from their 
culture; their culture cannot be separated from the land. 
For them, this oneness of land, people, knowledge and culture is the
only basis for meaningful consideration of biodiversity. The intellec-
tual enclosure movement is dissecting knowledge and fragmenting
flora and fauna into unrecognizable genetic bits and pieces. At stake
is the intellectual integrity of rural communities.
• Farming communities nurture biodiversity and respect the land. 
Ninety percent of the earth’s most biologically-diverse lands have 
no government protection, and are cared for exclusively by farming
communities and other traditional resource users. Almost all of the
e a r t h ’s most biologically diverse “hot spots” are home to or bordered
by the South’s farming communities. 
• Stewardship not exploitation is the preferred relationship with
natural resources. 
Non-industrial agrarian peoples use land, manage natural resources,
and pass on knowledge about them to future generations. Their rela-
tionship with nature is multi-dimensional and complex. In many rural
societies, the earth itself and life are sacred. Monopoly control over
the use and exploitation of living things, including food crops, is an
entirely alien concept to many farming societies. The notion of intel-
lectual property over living things is often a sacrilege. 
guild system
Medieval European association of people with
related work or interests (such as merchants or
craftsmen), established to maintain standards 
and protect its members interests. 
…But a bold peasantry, the country’s pride,
When once destroyed, can never be supply’d …
– Oliver Goldsmith, The Deserted Village, 1770
28
The Industrial (North) Perspective 
Landraces are essentially natural phenomena.
They have resulted from a combination of envi-
ronmental and human selection pre s s u res, over
millennia. Most of the credit goes to the enviro n-
ment and little goes to generations of farmers. 
Granting IPR for a landrace would be like trying to
patent the wheel a few thousand years after its
invention. This would amount to an inexcusable
monopoly under normal patent systems. 
How could you protect a landrace? Who would
receive the protection? What farm e r, from what
c o u n t ry, determined at what point in history ?
Why bother protecting landraces? Almost none of
those collected have any commercial value. It
would cost at least as much to monitor
g e rmplasm flows from farmers to industry as
f a rmers will ever receive in benefits from com-
pensation schemes.
W h e re a landrace is used in a commercial plant
v a r i e t y, breeders almost always extract and adapt
a gene or gene complex to become one of several
h u n d red components in a new plant variety. The
useful pro p e rties may not have been known, 
valued or even expressed in the farmers’ field.
F a rmers are best served by a free flow of
g e rmplasm. Eff o rts to assign benefits and pro v i d e
compensation for their raw material will just slow
innovation and restrict the spread of future benefits.
The Community (South) Perspective 
Landraces didn’t just happen. They are well-
adapted folkseeds that have been selected and
b red by generations of farmers for specific micro -
ecological niches. They are living examples of sus-
tainable agriculture that function in balance with
n a t u re, providing relatively secure food, and
requiring little or no external inputs.
Folkseeds in the field are no less modern than
the latest hybrid release. Each is the up-to-date
manifestation of active plant breeding. Both
involve human genius and both have value. Why
should only the corporate breeder be pro t e c t e d
and compensated?
The collective contribution of farmers could be
recognized. Compensation for using landraces need
not be tied to individuals, communities, or countries
but could be arranged through a global fund, on a
p rogram or project basis.
The same could be said of many inventions. Only
one in a hundred patents has some value. One in
a thousand has great value. The same is true of
folkseeds, although a low commercial re t u rn for
N o rt h e rn industry may be a huge re t u rn for Southern
f a rm e r s .
Recent biotech patent decisions (such as species-
wide patents on cotton and Bt) imply that the
patent holder need not know everything about the
patented material in order to benefit. 
F ree access would be fine if the principle were
applied uniform l y. The genius of informal, com-
munity plant breeders is unprotected, while that
of formal breeders is covered by IPR. Recognition
and restricted access are granted to industrial
innovators, but not to farm e r-innovators. The
N o rth can’t have it both ways. Free access must
apply across the board .
Landraces: The term used by plant
geneticists to describe literally thou-
sands of varieties of seeds used by
f a rmers the world over. 
Intellectual Pro p e rty Rights (IPR)
for Landraces
The Invisible Inventor
C o m m e rcial Irre l e v a n c e
Hidden Genius
“ F ree Access is Best”
TABLE 5
Agricultural Innovation and Intellectual Property
Southern Communities Challenge the Perspective of Northern Plant Breeders
Source: RAFI
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• Knowledge and innovation are collective creations. 
Innovation and adaptation to change have been a part of rural societies
for millennia, and knowledge has been passed on from generation to
generation. While specialized knowledge about plants and crops is
often entrusted to particular social groups or to honoured individuals,
it is not their private property. The body of knowledge is usually h e l d
collectively and inter- g e n e r a t i o n a l l y. Knowledge is carefully m a i n-
tained in trust for future generations and added to for the benefit of
the entire community. Individual ownership over living things or
knowledge about them is unheard of. 
Four Case Studies: Systems of Generosity and Gre e d
in Confli c t
What happens when systems of generosity are confronted with intellectual
property regimes? The four case studies that follow contrast the values
of many rural or indigenous societies with the present industrialized
intellectual property system. 
Food and Agriculture
Almost 90% of the South’s food re q u i rements are
met through local production. Tw o - t h i rds are
based on community farming systems.
90% of the world’s food crops are derived from the
S o u t h ’s farming communities and continue to
depend on farmers’ varieties in breeding pro g r a m m e s .
The direct commercial value derived from farm e r s ’
seeds and livestock breeds is considerably more
than US$5 billion a year.
99% of all plant breeders and other agricultural
re s e a rchers are based in rural communities.
C rop diversity is eroding at 1% to 2% per annum.
E n d a n g e red livestock breeds a re vanishing at rates
of 5% a year. Almost all farmers’ knowledge of
plants and re s e a rch systems could become extinct
within one or two generations.
Health and Medecine
Local: 80% of the South’s medical needs are met
by community healers using local medicine 
s y s t e m s .
Global: 25% (and growing) of western patented
medicines are derived from medicinal plants and
indigenous pre p a r a t i o n s .
Market: The current value of the South’s medicinal
plants to the North is estimated conservatively a t
US$32 billion annually.
E x p e r t i s e : Well over 90% of all health practi-
tioners are community healers.
R i s k : Almost all local knowledge of medicinal
plants and systems, as well as the plants them-
selves, could disappear within one generation. 
E n v i ronment and diversity
Almost 100% of the biodiversity “hot spots” are in
a reas nurt u red by indigenous communities and/or
b o rdering the South’s farming communities.
The wild relatives of almost every cultivated cro p
a re found in biologically-diverse regions of the
South and are nurt u red by indigenous communities.
90% of the world’s most biologically-diverse lands
and waters have no government protection and are
n u rt u red exclusively by rural communities.
99% of all practiced biodiversity expertise re s i d e s
in indigenous and other rural communities.
Rain forests are coming down at a rate of 0.9% per
annum and the pace is picking up. Much of the
e a rt h ’s remaining diversity could be gone within
one or two generations. 
TABLE 6
The Role of Community Knowledge in Global Development
Source: RAFI
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CASE STUDY T H R E E
Endod Patents take
the Public Spirit out of
the Public Sector
Ethiopian mothers have bathed their children with a
shampoo squeezed from their local endod or soapberry
plant for as long as anyone can remember. Many have
also used endod extract to purify water. Use of the plant
seems to reduce the incidence of schistosomaisis
among children who catch the disabling disease from a
snail in river water.
For well over two decades, Dr. Aklilu Lemma and his col-
leagues in Ethiopia worked with funding from Canada’s
International Development Research Centre (IDRC) to
see if endod could become a weapon against schistoso-
maisis worldwide. So successful was their work that
Lemma was invited to the University of Toledo in the
United States in 1990 to receive an honorary doctoral
degree for his humanitarian efforts. 
At dinner with university President Frank Horton and
campus scientists the night before receiving his degree,
Lemma was asked if endod might be effective against
zebra mussels, a US$5 billion a year scourge affecting
shipping on the nearby Great Lakes. Since endod suc-
cessfully kills snails, Lemma assumed it might be effec-
tive against mussels and drew up an experiment on the
spot using an endod sample he had brought from
Ethiopia. 
The next day, after receiving his degree, Lemma was
informed that his experiment had worked. Four months
to the day after the Ethiopian scientist won his doctoral
prize, the University of Toledo filed for US patents on the
use of endod against zebra mussels. The patents were
granted in 1994.
In Febru a ry 1995, Lemma—who heads the Ethiopian-
based Endod Foundation, a non-profit research institute
with branches throughout Africa—wrote to Frank
Horton. He requested access to the patents in order to
extend the Foundation’s research on endod’s use against
schistosomaisis and banana and cassava pests, and to
develop its commercial use in shampoos and deter-
gents. There had been a “gentleman’s agreement” that
Ethiopia would share in royalties arising from patent
products, that Ethiopian farmers would grow the crop
for export to American manufacturers using endod
against zebra mussels, and that the Foundation would
also be free to continue its own research. Horton
responded to Lemma, congratulating him and Ethiopia
on their “high-minded” goals, but advising him that the
two patents were available for a license fee of US$50,000
(plus 2.5% royalty charges and legal fees) or for outright
purchase at US$125,000 plus legal costs. 
C A S E  S T U D Y O N E
Generosity… 
An Inherited Trait?
When Frank Majestic got involved with the
Conserve Program in Mindanao in the Philippines,
farmers in the region were fed up with the high
input costs of Green Revolution rice. They were
anxious to do their own breeding as they had done
in the past. The problem was that the traditional rice
varieties were no longer around. Majestic and the
farmers wrote to the International Rice Research
Institute (IRRI) and eventually received more than 
a hundred farmers’ varieties that had first been 
collected in their area decades before. Older farm e r s ,
however, remembered many more. 
Finally, Majestic organized an expedition into the
surrounding hills to meet with Muslim farmers.
Tr a d i t i o n a l l y, the farmers associated with the
Conserve campaign in the valleys had been in a
state of semi-war with the hillside Muslims. Despite
this, the Muslim farmers willingly gave them almost
three hundred rice varieties never collected by IRRI.
With these, the valley farmers launched their own
intensive breeding programs once again. The new
varieties they are developing are free to other far m-
ers as long as they promise to keep them out of the
hands of companies that might want to patent them.
C A S E  S T U D Y T W O
A “Wild” Idea?
For as long as anyone can remember, farmers in
Panama have used sap from the stem of a local vine
(Omphalea diandra) to protect their stored beans
from beetle infestation. The same sap has also been
used to heal wounds and relieve headaches. Once
every several years a migratory moth venturing
between Mexico and South America stops in
Panama to feed from the vine leaves. On these
occasions, the vine produces a powerful toxin mak-
ing its leaves inedible to all save the moth that con -
centrates the toxin. The local community, observing
this occasional migration effect, then harvests the
toxin. Based on their information, Northern phar-
maceutical companies are now evaluating the toxin
(known as DMDP) as a pharmaceutical for use
against AIDS, diabetes, and cancer, and as a food
preservative. 
“Indigenous people are willing to share our knowledge with
humanity provided we determine when, where and how it is
used. At present the international system does not recognize or
respect our past, present and potential contributions.”
(Final statement, Consultation on Indigenous Peoples Knowledge and Intellectual Pro p e rty Rights, Suva, Fiji, 1995)
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C A S E  S T U D Y F O U R
Humanitarian Patents: 
The US Pioneers a New
Approach to Foreign Aid
Early in the 1990s, the US National Institutes of Health (NIH) and the US Centres
for Disease Control (CDC) sent medical expeditions out in search of remote
human communities that might have variant strains of lymph cells useful in
treating immune deficiency diseases including cancers and AIDS. In 1993, the
Guaymi General Congress, an indigenous peoples’ council, learned that a 26-
year-old Guaymi mother of two living on or near a banana estate in western
Panama was the subject of a US government patent claim. Her cheeks had been
scraped, some hair follicles had been removed, and blood samples had been
taken for examination by a long-term storage facility in the US. Medical doctors
had not told her or the Guaymi community of their patent interests or her poten-
tially bright commercial future. 
With support from the Community Biodiversity Development and Conservation
p rogram, leaders of the Guaymi Congress flew to Geneva to question GATT off i c i a l s
and publicize the patent claim at a Biodiversity Convention meeting. The Guaymi
wanted to know if the US government had the right to patent human cell lines
under the proposed new GATT accord and if they could be protected under the
new Biodiversity Convention. Within weeks, the US government announced i t
was dropping the patent application, but only because it was not commerc i a l l y
v i a b l e .
Meanwhile, in the Pacific, other US medical teams had similarly surveyed com-
munities in the Solomon Islands and Papua New Guinea. In early 1994, NGOs
learned that patent claims were pending on the cell lines of individuals in both
countries. When the UN Ambassador for the Solomon Islands complained to the
US Secretary of Commerce (the formal applicant for external patent rights), he
was told that the American government was perfectly within its rights to patent
human material from citizens of other countries. Later US government officials
advised the ambassador that the claims would be dropped. Yet in March 1995,
the US Patent Office granted a patent to the US government on the cell line of a
20-year-old Hagahai man from Papua New Guinea. 
When this news reached the Pacific late in 1995, governments protested at
another meeting of the Biodiversity Convention. American authorities did not
respond officially but informally reported that the claim had only proceeded
because the Hagahai themselves had specifically requested it. According to
American scientists involved in human genetic research, the government had
made a royalty-sharing deal with the Hagahai, with approval of the PNG
Government, because they needed humanitarian aid. 
By May 1996, the US government had provided no written corroboration of a
royalty-sharing agreement. No proof of the Hagahai’s prior informed consent
had been offered, and no official evidence was provided that the Solomon
Islands patent had been dropped. 
If the US is acting on the Hagahai’s request, this is the first time a government
has granted itself a patent on a foreign citizen’s cell line for humanitarian rea-
sons. The Hagahai might have preferred receiving the US$10,000 filing fee or the
estimated US$250,000 in legal fees that are needed to maintain the average
American patent. Unless real help comes soon, the only Hagahai left may be the
one immortalized in the American patent repository.
Green Revolution
A massive and controversial agricultural research
and production strategy which aimed to increase
the output of staple grains in the South starting in
the 1960s. 
cell line
A sample of cells removed from any organism that




Use this chapter to gain an overview of the new
life industries and how they operate, including
their methods of gathering genetic materials
and gaining intellectual property rights in the
areas of 
• agriculture
• medicinal plants and pharmaceuticals
• microorganisms
• human genome research.
Other topics covered in this chapter include
• corporate concentration in the life industr y
• intellectual property and ex situ conservation
• effects of bioprospecting and biopiracy on
the governments and peoples of the South
• N o rt h e rn corporate control of microbial 
c o l l e c t i o n s
• ethical and practical implications of human
DNA and genome patenting
• the activities of the Human Genome Diversity
Project.
For additional information, see Appendix A: A
Short History of the Patent System, showing
some of the precedent-setting incursions of
intellectual property regimes into animal, micro-
bial, plant and human life. Refer to Appendix C:
Biopiracy and Biop rospecting Activities f o r
i n f o rmation on many of the corporations and
re s e a rch institutes that are tapping indigenous
knowledge in their growing quest to develop
new medicines and pharmaceuticals. S e e
Appendix D and Appendix E for information on
the top corporations involved in various life
i n d u s t ry sectors.
Chapter 4I
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Biotechnology and the Life Industries
Biotechnology research was initially conducted by small, specialized
industry “boutiques” who were supported by big corporations on a 
contractual basis. In recent years there has been a gradual shift, with 
the giant corporations now playing a more direct and dominant role in
b i o t e c h n o l o g y, and devoting more of their research and development to
in-house biotechnology programmes. Equity investments and buy-outs
of the smaller biotechnology companies by large corporations have
become common.
For example:
• H o ffmann-LaRoche of Switzerland now owns Genentech, the larg e s t
biotech company in the USA.
• In 1994, Limagrain acquired 67% of Biotechnica International’s farm
seed business.
• In July 1996, Monsanto acquired controlling interest of Calgene, a
leading agricultural biotechnology company.
• In September 1995, Pioneer Hi-bred entered a $51 million deal with
Mycogen, a plant biotechnology company that specializes in biologi-
cal pest control. This gives Pioneer easy access to Mycogen’s g e n e
b a n k of patented Bt genes.1 3
Corporate concentration and integration are not new. The 1970s and 1980s,
for example, saw a steady reduction in the number of companies domi-
nating agribusiness and the pharmaceutical trade. But in recent years, 
the new biotechnologies have led to dramatic changes in the structure of
these industries. Scientists can and do transfer genes across the species
barrier from humans and animals to microorganisms, and from animals
to plants. This has blurred the distinctions between industry sectors, and
single corporations have diversified into all fields which use living
o rganisms for industrial production, such as food processing, seed 
production, plant breeding, agrochemicals, veterinary medicines, and
human pharmaceuticals.
The life industry is perhaps best exemplified by Novartis, the titanic cor-
poration formed by the $27 billion merger of Swiss giants Sandoz and
Ciba-Geigy in early 1996. It’s difficult to classify Novartis as “a phar-
maceutical firm” or an “agrochemical company”, Novartis is the world’s
number one agrochemical corporation, the second largest seed firm, the
third largest pharmaceutical firm, and the fourth largest veterinary medi-
cine company. Novartis also contracts with human genome companies in
the quest to gain proprietary access to human genes. Approximately 59%
O V E RV I E W
The new life industries are the main
players in the business of intellectual
property and biodiversity. They con-
trol present and possible future
flows of genetic resources and
knowledge from the South to the
North, in four important areas of bio-
diversity: agricultural species, medi-
cinal plants, microorganisms, and
human genetic material. Corporate
concentration is high in the life
industries, and large corporations
are now using intellectual property
rights to appropriate community
knowledge and privatize biological
materials for their own profit. Recent
e fforts to patent human genetic
materials gathered from indigenous
peoples raise serious moral and 
ethical dilemmas.
THE LORDS OF LIFE
of the company’s revenues comes from drugs, 27% from agicultural
products, and 14% from food products. 
A g r i c u l t u re
It is now well known that the world’s main food and livestock species
have their centres of genetic diversity in the South, thanks to generations
of farmer-breeders who domesticated and then adapted food species to
millions of micro-environments. But the significance of this has not yet
been fully grasped. 
Farmers of the South, who grow most of the earth’s remaining agricul-
tural genetic stock, hold the key to the world’s food security. All the
w o r l d ’s farmers, and all public sector and corporate plant breeders, ulti-
mately depend upon what they grow. It is Southern farmers who cultivate
the agricultural biodiversity that will enable the earth’s food species to
adapt to changes, whether evolving pests, diseases, climate change or
human intervention. It is to farmers’ fields in the South that plant breeders
must return in search of plants with desired genetic characteristics. 
The surest and cheapest way to keep this genetic diversity alive is to keep
it growing in farmers’ fields. In situ c o n s e r v a t i o n is now recognized by
the world’s agricultural research establishment as an important element
in the conservation of agricultural biodiversity and is promoted in the
Biodiversity Convention. However, farmers face government policies
and commercial pressures that constantly push them to replace their 
own varieties with high-tech, high-input, higher-yielding varieties of 
staple grains and livestock breeds.
But in situ conservation is not the only or most practiced conservation
approach in the world of industrial agriculture. Ex situ c o n s e r v a t i o n i s
much more common. 
Most of the world’s gene banks are in the North. Together they contain
hundreds of thousands of seed samples, collected from farmers’ fie l d s
and stored in giant refrigerators, for use by the seed industry and public
sector plant breeders. About 40% of the world’s most valuable ex situ
agricultural genetic material is held in just twelve gene banks, whose
seeds come largely from the South and whose funding comes mostly
from industrialized country aid budgets. 
These gene banks came under the legal control of the UN Food and
Agriculture Organization (FAO) in October 1994. They are run by a net-
work of International Agricultural Research Centres which make up the
Consultative Group on International Agricultural Research (CGIAR).
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gene bank
Humidity- and temperature-controlled facilities
where seeds and other reproductive materials are
stored for future use in research and breeding
programs. 
in situ conservation
On-site conservation of ecosystems and natural
habitats, and the maintenance and recovery of
viable populations of species in their natural
surroundings. 
ex situ conservation
Conservation of genetic materials outside their
natural habitats. 
Consultative Group on International Agricultural
Research (CGIAR)
An informal network of sixteen International
Agricultural Research Centres in Latin America, 
the Middle East, Africa, Asia and Europe. 
Proud swells the tide with loads of freighted ore,
And shouting Folly hails them from her shore;
Hoards, even beyond the miser’s wish abound, 
And rich men flock from all the world around. 
– Oliver Goldsmith, The Deserted Village, 1770
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Refer to Appendix D for tables showing the top
ten corporations in five industry segments:
a g rochemicals, seeds, food and beverages,
pharmaceuticals, and animal health.
They have been used mainly for agricultural research in Asia, Africa and
Latin America, but the North has also benefited handsomely from the
agricultural genetic material they contain. RAFI has estimated that farm-
gate prices in Europe, North America, Australia and New Zealand have
risen by US$5 billion a year, thanks to seed improvements based on
genetic material from these twelve gene banks alone.1 4
Intellectual property claims over plants have become a daily occurrence.
Industries in the North now commonly use seeds from the South (includ-
ing those from gene banks) to develop plant varieties that are subsequently
protected by Plant Breeders’ Rights or patents. About a decade ago,
farmers and governments from the South started to point to the inequity
of this. W h y, they asked, are the plant varieties that have been bred by
Southern farmers considered the common heritage of all people, when
industry can claim exclusive monopoly rights over plant varieties
derived from them? 
Faced with mounting dissatisfaction, the FAO introduced the concept 
of Farmers’ Rights in 1985 as a counter-weight to intellectual property
claims over plants. In 1992 the Biodiversity Convention established that
governments had sovereignty over the biodiversity within their borders
and could control access to it. So far, however, Farmers’ Rights is little
more than a compelling idea, and the Biodiversity Convention excludes
from coverage all the valuable ex situ collections that existed before it
came into effect. Efforts are afoot to address both these problems within
the Biodiversity Convention and at a series of international agricultural
meetings in the late 1990s. Farmers’ Rights and access to genetic
resources are high on the multilateral agricultural agenda.
During negotiations over the final text of the Biodiversity Convention,
Northern governments successfully lobbied to remove all material already
held in ex situ biological collections from the Convention’s scope. As a
result, the material was deemed to belong to those who deposited it, and
not to the countries it was taken from, as would be the case with material
collected after the Convention came into effect. The CGIAR collections
of Southern agricultural genetic resources were thus excluded from the
Convention, but immediately after it was signed, steps were taken to
clarify the legal status of these collections and ensure that they remained
accessible in the public domain. 
In October 1994, the CGIAR and FAO signed an agreement which made
all the material in these gene banks the property of the FAO to hold in
trust for the world community. When this agreement was signed, it was
understood that the FAO would also move to place these collections
under the Biodiversity Convention. Steps are now underway to do this,
possibly at the Conference of the Parties to the Convention in A rg e n t i n a
in November 1996.
Cotton is Still King in
the World of Pa t e n t s
Eli Whitney got the (cotton) ball rolling with
his patent on the cotton gin, the premier inven-
tion of Britain’s agricultural re v o l u t i o n .
W h i t n e y ’s machinery helped end India’s textile
e x p o rts to Europe, but the South’s patent
p roblems continued. 
In 1990, an American entomologist named
Sally Fox won two Plant Variety Protection cer-
tificates (also known as plant breeders’ rights)
for Coyote and G reen c o l o u red cottons, which
she admits originated in Central America.
Capturing the enthusiasm for natural colours,
jean textile makers advertised that their cot-
tons came “from the ancient peoples of the
Americas”. Nice as it was to receive the plau-
dits, indigenous farmers from Mexico to Peru
received none of the pro f i t s .
A couple of years later, W.R. Grace, one of the
w o r l d ’s largest specialty chemical companies,
bought a biotechnology re s e a rch company
known as Agracetus (Agracetus was bought
out by Monsanto in 1996) and picked up a
patent on transgenic cotton. Grace’s claim
c o v e red all transgenic cotton, re g a rdless of the
biotechnology method used to produce it or
the germplasm involved. In short, W.R. Grace
would have taken charge of the future of high-
tech cotton breeding for the next quart e r-
c e n t u ry. The farm-gate value of the cotton
c rop, critical to the economies of scores of
South countries, is over US$20 billion a year. 
But the U.S. government revoked the patent.
Outraged, the government of India also disal-
lowed the patent. Unfort u n a t e l y, as Indian 
scientists continued their own work on insect-
resistant cotton, they ran afoul of a diff e re n t
patent held by Monsanto, one of the world’s
l a rgest life industries. This one covered most
i n s e c t - resistance for cotton. Indian farm e r s
who have been breeding cotton for several
thousand years can get a license fro m
Monsanto to use its technology, if they can
just come up with US$7.7 million … and the
legal fees.
Intellectual property rights over the materials in these FAO/CGIAR 
collections remains a highly contentious issue. On one side, CGIAR
researchers have felt the pressure of intellectual property trends in the
private sector. Whether to protect their public sector research from
appropriation by the private sector or to take advantage of commercial
opportunities which they believe patents might facilitate, they have
pushed to claim intellectual property rights over some of the plant mate-
rials they hold and develop. Others within the CGIAR centres, and many
outside them, strongly oppose this direction, arguing that it would eff e c-
tively privatize their agricultural genetic resources, whatever the motive
for doing so. 
Since the mid-1970s, critics have argued that patents on food crops are a
threat to world food security, because they place the genetic base of the
w o r l d ’s food supply in private hands. In recent years, extremely broad
patent claims over entire agricultural species (including cotton, soybeans
and Bacillus thuringiensis or Bt, a soil bacterium with pesticidal proper-
ties) have heightened these fears, and led to legal challenges in Europe,
India and North America in 1994 and 1995.
Medicinal Plants
The medicinal knowledge of farming and indigenous communities is
already being appropriated with impunity by Northern corporations. 
Yet the contribution of rural peoples to corporate profits goes larg e l y
unacknowledged, unprotected and unrewarded, while research into 
medicinal plants becomes one of the fastest growing sectors of the 
life industries. 
A picture of piracy is emerging that indigenous knowledge holders are
analyzing with great interest and growing dismay. As a result, indigenous
peoples and rural communities are now doing research of their own and
are organizing to protect their intellectual integrity in the face of an
intellectual property system which currently offers them no protection.
M i c robial Biodiversity
Intellectual property rights over agricultural biodiversity and medicinal
plants is now on the agenda in international forums. But microorg a n i s m s
(or microbes) have been virtually ignored in the debate about biodiversity
and intellectual property, despite their immense importance in nature,
their growing value to the biotechnology industry, and their specific
inclusion under the World Trade Org a n i z a t i o n ’s intellectual property
agreement. They should be considered as carefully as agricultural and
medicinal plant species.
Unlike crop seeds and medicinal plants, microorganisms which have
been isolated and characterized by scientists are much more easily and
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Agenda 21
A comprehensive action plan on the environment
adopted at the Earth Summit in 1992. 
What are Farm e r s ’
R i g h t s ?
The principle of Farmer’s Rights, endorsed by
the FAO in 1989, recognizes the fact that farm e r s
and rural communities have contributed greatly
to the creation, conservation, exchange and
knolwdge of genetic re s o u rces, and that they
should be recognized and re w a rded for their
past and ongoing contributions. Farm e r s ’
Rights acknowledge that farmers who have
consciously selected and improved crop genetic
re s o u rces since the origins of agriculture
should be rewarded no less than plant breeders
who benefit from Plant Breeder’s Rights. Many
governments and NGOs have embraced this
principle of Farmers’ Rights, in recognition of
the innovative role that farmers and rural com-
munities play in the conservation and further
development of genetic resources, and of their
right to benefit from it.
It is important to stress that Farmers’ Rights
extends beyond the issue of compensation for
farmers and farming communities; it includes
rights to land and secure tenure, the farmer’s
fundamental right to save seed and exchange
germplasm, and the right of farming communi -
ties to “say no”, by choosing not to make their
germplasm and knowledge available.
It has been accepted, however, that farm e r s
have the right to Germplasm, Information, Funds,
Technologies and Farming/Marketing Systems
(GIFTS). Others outside the FAO, including
Agenda 21 and the Biodiversity C o n v e n t i o n ,
have also adopted the principle of Farm e r s ’
Rights, and the government of India is draft-
ing legislation that would establish Farm e r s ’
Rights in law. The financing and implementation
of Farmers’ Rights will be addressed by 
several international agricultural meetings in
the coming years. 
Refer to Appendix C for an overview of many
corporations and research institutes that are
scouring the globe for plants and other com-
m e rcially-useful organisms with medicinal
properties. The table shows how industries are
tapping indigenous knowledge in their growing
quest to develop new pharm a c e u t i c a l s .
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I n s t i t u t i o n
1 . Australian Government Analytical Laboratories
2 . Belgian Coordinated Collections
3 . National Bank for Industrial Micro o rg a n i s m s
4 . Czech Collection of Micro o rg a n i s m s
5 . Collection Nationale de Culture s
6 . Deutsche Sammlung 
7 . National Collection of Agricultural and Industrial Micro o rg a n i s m s
8 . National Institute of Bioscience and Human Te c h n o l o g y
9 . K o rean Cell Line Research Foundation
1 0 . K o rean Collection for Type Culture s
1 1 . K o rean Culture Collection for Micro o rg a n i s m s
1 2 . C e n t r a a l b u reau voor Schimmelculure s
1 3 . All-Union Institute of Genetics and Industrial Cultivation
1 4 . All-Union Centre for Antibiotics (VNIIA)
1 5 . Institute of Biochemistry (IBFM-VKM)
1 6 . C u l t u re Collection of Ye a s t s
1 7 . Coleccion Espanola de Cultivos de Ti p o
1 8 . C u l t u re Collection of Algae and Pro t o z o a
1 9 . E u ropean Collection of Animal Culture s
2 0 . I n t e rnational Mycological Institute
2 1 . National Collection of Food Bacteria
2 2 . National Collection of Type Culture s
2 3 . National Collection of Yeast Culture s
2 4 . National Collection of Industrial and Marine Bacteria Inc.
2 5 . ARS Culture Collection
2 6 . American Type Culture Collection
C o u n t ry
A u s t r a l i a
B e l g i u m
B u l g a r i a
Czech Republic
F r a n c e
G e rm a n y
H u n g a ry
J a p a n
K o rea (Republic of)
K o rea (Republic of)
K o rea (Republic of)




S l o v a k i a











1 9 8 8
1 9 9 2
1 9 8 7
1 9 9 2
1 9 8 4
1 9 8 1
1 9 8 6
1 9 8 1
1 9 9 3
1 9 9 0
1 9 9 0
1 9 8 1
1 9 8 7
1 9 8 7
1 9 8 7
1 9 9 2
1 9 9 2
1 9 8 2
1 9 8 4
1 9 8 3
1 9 9 0
1 9 8 2
1 9 8 2
1 9 8 2
1 9 8 1
1 9 8 1
Source: World Intellectual Property Organization
TABLE 7
International Patent Culture Depositories under the Budapest Treaty
reliably maintained under artificial conditions than in their natural habitat.
Ex situ microbial collections are therefore of utmost importance to scien-
tists and the life industries. Like ex situ seed collections, the world’s
microbial collections are mainly located in the North and hold biological
material from all over the world. All microbial collections that predate
the Biodiversity Convention fall outside its scope. This means that any-
thing deposited in a biological culture collection before December 1994
is the property of the depositor, regardless of its country of origin or
whether anybody in the country of origin knows it is there. 
RAFI has examined deposit records from several microbial collections,
and has carefully analysed those for the largest one of them, the A m e r i c a n
Type Culture Collection (ATCC) in Rockville, Maryland. Analysis reveals
that thousands of biological specimens from the South are kept in the
ATCC. Dozens of them are already patented by Northern corporations
such a Bristol-Myers, Pfizer and Eli Lilly, and many others are under
patent claim.1 5 Though other microbial collections have not been analysed,
it can be assumed that the same holds true for them. 
All patent laws require inventors to fully disclose their inventions to the
Patent Office. For biotechnology patents involving microorg a n i s m s ,
inventors must deposit a biological sample in a patent culture depository
recognized internationally by the Budapest Treaty on the International
Recognition of the Deposit of Microorganisms for the Purposes of
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patent culture depository
Recognized institutions in 15 countries that
contain deposits of living materials which are
▲ Centres of origin of domesticated plants and
animals
1 turkey, sunflower, tepary bean
2 avocado, cocoa, sweet potato, maize, 
runner bean, tomato
3 llama, guinea pig, alpaca, cotton, lima bean,
peanuts, peppers, potato
4 pineapple, yam
5 goose, cattle, pig, grapes, barley, olive, rye
6 yam, watermelon
7 finger millet, sorghum
8 reindeer
9 horse
10 bactrian camel, alfalfa, millet, hemp
11 foxtail millet, soya bean
12 yak
13 coconut, breadfruit
14 barley, dates, onion, peas, wheat, ass, 
dromedary, sheep, goats
15 zebu, chicken, pig, water buffalo, banana,
rice, yam, tea
Patent Procedure. These deposit sites are administered by the Wo r l d
Intellectual Property Organization (WIPO) in Geneva. Twenty six 
institutions in 15 countries are officially recognized for the purpose of
patent procedure, of which 23 are in the North. Together, they contain the
living materials (microorganisms, genes, seeds, animal embryos, human
and animal cell lines) that are the basis for virtually all biopatents. Each
facility has a catalogue of its holdings which often indicates the source
of the material. Researchers can find useful information about the
sources of patented materials by analyzing the data in these collections. 
Human Patenting
“Over the last 200 years, non-Aboriginal people have taken our land,
language, culture, health — even our children. Now they want to take
the genetic material that makes us Aboriginal people as well.”
(John Liddle, Director, Central Australian Aboriginal Congress).1 6
If intellectual property control over food species first raised ethical ques-
tions about trends in life patenting, it was patent claims over human
genetic material that really moved people, especially indigenous people,
to action. When news of patents and patent claims over human cell lines,
genes and DNA fragments began to spill off the pages of obscure scien-
t i fic and legal journals and into the wider media, ordinary people joined
ethicists, public sector scientists and public-interest research groups to
question the direction that intellectual property laws were headed. W h e n
they realized that intellectual property was quietly evolving to include
monopoly control over inherited human traits, people all over the world
began to see that patenting of human parts was the logical extension of 
a system that already permitted monopoly control over living org a n i s m s
and their inherited traits. 
The scientific search for genetic causes and resistance to all manner of
human conditions and diseases is picking up speed. Scientists in the
industrialized world are hoping to find profitable cures for everything
from cancers to asthma and obesity, from sickle cell anemia to diabetes
and baldness. In the commercially-driven business of biomedical research,
patents are now being sought and granted over human genetic material
which researchers hope some day will have commercial value. T h o u g h
patent laws in some countries prohibit the patenting of human beings,
there is nothing in most countries’ patent laws or in the W TO T R I P S
agreement to prohibit patenting of human genetic material. Pieces of the
human genetic code and human cell lines are being treated under patent
law as if they were microorganisms like fungi and bacteria, and are now
being patented in industrialized countries. 
Patent database searches reveal that at least 100 human cell lines are
currently the subject of patent claims in the United States. One company
40
Refer to Appendix A for highlights of some of
the precedent-setting incursions of intellectual
property laws into plant, animal, microbial and
now human life. 
the basis for virtually all life patents. 
Human Genome Diversity Project (HGDP)
An international research effort to collect samples
of human tissues from distinct populations
worldwide. 
Human Genome Project
An international endeavour among geneticists to
identify and describe the estimated 100,000 genes
that control inherited traits of human beings. 
Human Genome Organization (HUGO)
The international organization that governs the
Human Genome Project and the Human Genome
Diversity Project. 
genome
All of the genetic material in the chromosomes of
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estimates that the US Patent and Trademark Office has already issued
more than 1,250 patents on human gene sequences.17 All this is occurring
in a policy vacuum.
In 1993, as the implications of life patenting were seeping into public
consciousness, an international initiative called the Human Genome
Diversity Project (HGDP) was launched and became a lightning rod
for many of the concerns that people were raising about life and human
patenting. Initially the brainchild of Northern anthropologists and
geneticists, the project was later adopted by the multi-million dollar
Human Genome Pro j e c t , which in turn is governed by the H u m a n
Genome Organization (HUGO).
The HGDP’s stated purpose was to broaden study of the human genome
beyond the DNA of Europeans and North Americans, and to gather tissue
samples that would help geneticists and social scientists trace the early
migration of peoples around the globe. It initially proposed to collect
some 15,000 samples of blood, hair and cheek scrapings, from 722 
distinct ethnic groups which they dubbed “isolates of historic interest”.
Not surprisingly, the initiative aroused concern among its targets, the
majority of them indigenous peoples, who had not been consulted about
the project’s intentions to sample and analyze their body tissues. T h e i r
concerns were far broader than intellectual property, but one of their fears
was that indigenous people’s genes would be patented for corporate profit. 
As if to confirm their fears, three patent claims by the US government
on cell lines from indigenous people in Panama, Papua New Guinea
(PNG) and the Solomon Islands, were unearthed in late 1993 and early
1994. In March 1995, the PNG patent was granted (see Case Study Four
in Chapter Three). 
These revelations sparked opposition to human patenting by indigenous
p e o p l e s ’o rganizations around the world. They raised their concerns pub-
l i c l y, and took them to the W TO and the Biodiversity Convention. T h e y
joined many Northern organizations in calling for a comprehensive global
review of life patenting, and human patenting in particular. Debate about
human patenting is expected in several international forums in the years
ahead. It has already been raised by UNESCO’s International Bioethics
Committee and was discussed at the Conference of the Parties to the
Biodiversity Convention in Jakarta in November 1995. These two bodies,
along with the World Health Organization, are all likely to debate the
issue in 1996 and 1997.
Confronted with questions about whether human genes collected by the
project could fall under patent monopoly, the HGDP has been unable to
allay the fears of many people. The project’s proponents have repeatedly
shifted their position on patenting. Initially, they gave it no consideration
and argued that the material would have no commercial value. In a 1993
The Human
Genome Project
The Human Genome Project is a worldwide
endeavour funded by Nort h e rn govern m e n t s
and launched in 1988 by scientists to map the
human genome. Using new technologies, they
set out to describe the chemical composition
of each of the estimated 100,000 genes that
c o n t rol the inherited part of every person’s
makeup. The project erupted in controversy in
1992 when Craig Ve n t e r, a scientist working on
the project, and his employer, the United
States govern m e n t ’s National Institutes of
Health, staked a US patent claim on 2,750 DNA
fragments from the human brain which Ve n t e r
had identified but whose functions in the body
w e re unknown. 
Nobel laureate James Watson described the
patent claim as “sheer lunacy”, and other sci-
entists expressed fears that the rush to patent
and commercialize pieces of the human
genome would hinder advances that should be
the “prized possession of all humanity”.1 8
Ve n t e r’s patent claim was rejected because it
failed to meet the basic criteria for patentability,
but not before it had sparked a virtual bidding
war among genetic re s e a rchers. Researc h
facilities in the United Kingdom and Japan fol-
lowed Ve n t e r’s lead and filed for similar
patents on thousands more human DNA frag-
ments. Many concerned scientists in Euro p e
publicly opposed these patent claims, arg u i n g
that their work should remain in the public
domain. 
In December 1993, French re s e a rchers work-
ing on the Human Genome Project unveiled a
first-generation map of about 90% of the
human genome, stressing that they would
continue make their re s e a rch freely available.1 9
In November 1993, the Medical Researc h
Council in Britain announced that it would no
longer seek patents on gene segments discov-
e red as part of the Human Genome Pro j e c t .2 0
Craig Ve n t e r, in the meantime, became a multi-
m i l l i o n a i re as one of many publicly-funded 
scientists who set themselves up in private
business in an eff o rt to profit from new human
genome technologies.2 1 The legal re p e rc u s-
sions of Ve n t e r’s patent claim are likely to be
played out in the courts for years to come. The
policy debate that it provoked has just begun. 
document, they acknowledged that collected tissue samples would 
“provide valuable information on the role played by genetic factors in
the predisposition or resistance to disease”, but continued to argue that
the material was unlikely to have any commercial value. They nonethe-
less agreed (in the unlikely event that the material proved commercially
useful) that the HGDP itself would not seek patents. Then they proposed
that if human DNA collected by the project did have a commercial
application, the peoples involved should benefit fin a n c i a l l y. Observers
found it hard to keep up with the shifting assumptions behind these
statements. They asked how, in the absence of laws to enforce it, the
H G D P could control whether others patented the material once it
became publicly available. 
N o b o d y, however, had trouble understanding the January 1995 conclusion
of an international meeting of human genome scientists held in Paris,
attended by HUGO’s president. That meeting stated that the patent system
was the “mechanism of excellence” for commercializing the results of
the Human Genome Project.2 2 The trend is clear. Intellectual property
rights, if not checked, will soon be applied routinely to all living things,
including people. 
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Use this chapter to understand how and where
to take action on intellectual property issues,
both nationally and internationally. Based on the
suggestions provided, farming communities,
activists and policy makers can develop strate-
gies for influencing the many institutions that




Strategies and Options for Change
In one guise or another, intellectual property is now an issue for many
international agencies. It is on the agenda for every government that has
joined or is planning to join the World Trade Organization. For a short
period of time, many opportunities exist to influence the evolution of
intellectual property on the international level, and to propose alterna-
tives to existing intellectual property concepts and laws. 
Between now and 1999, however, it will require a concerted effort both
nationally and internationally. To be effective, governments, non-govern-
mental organizations and rural communities will have to mount a sustained
and informed critique of existing intellectual property regimes. T h e y
will have to develop viable alternatives to the new enclosures and work
together to address the issue of intellectual property rights in all its guises
and in all relevant arenas.
It is impossible to anticipate or list all of the many places where concerns
about intellectual property could be addressed. It is possible, though, to
identify the categories of issues that are likely to be debated, including:
• F a r m e r s ’ R i g h t s
• bioprospecting, biopiracy and intellectual property
• patents and indigenous knowledge
• alternatives to intellectual property and new forms of protection for
rural communities
• life patenting in general
• patenting of human genetic material.
Most of these issues suggest the type of forum where they might be
addressed. All of them will have to be dealt with nationally, regionally,
and internationally. Rural communities, peoples’ o rganizations and
NGOs around the world will have to work to ensure that these issues are
addressed at the national level. National debates and policies in turn can
e ffect regional and international decisions. Whatever the level of action,
the objectives remain the same:
• to achieve tangible recognition for the intellectual integrity and 
innovation systems of rural communities and peoples
• to develop mechanisms to protect the intellectual integrity of rural
and indigenous peoples
• to implement Farmers’ R i g h t s
• to achieve national and international agreements that entrench these
a c h i e v e m e n t s
O V E RV I E W
Between now and the World Tr a d e
O r g a n i z a t i o n ’s 1999 review of its
intellectual property provisions, there
are many opportunities to affect the
evolution of intellectual property
regimes and to propose alternatives
both nationally and internationally.
Actions can be taken within countries
and internationally to protect the
intellectual integrity of rural commu-
nities, and to open the life patenting





Rural people’s organizations and others outside government can play a
critical role in convincing “developing” and “least developed” country
governments that they have time to consider a range of intellectual prop-
erty options before implementing the intellectual property provisions of
the World Trade Organization. Their first real option is to make no leg-
islative changes in the short term, and to take full advantage of the time
they have to weigh the alternatives in the area of intellectual property.
They might take account of the following considerations:
• The vast majority of patents originate in the industrialized world. A
1995 RAFI study of plant patents worldwide, for instance, revealed
that 76% were held in the US, and that industrialized countries
(European states, the US, Canada, Japan, Australia, New Zealand 
and Israel) accounted for nearly 100%. Corporations held 79% of the
plant patents covered by this study. The South was under- r e p r e s e n t e d
despite the fact that much of the patented germplasm originated there.
A few plant patents originated in the South, but in all such cases, the
patent assignee (or owner) was a Northern corporation.2 3
• It is not necessary to establish utility patent legislation over plants in
order to meet W TO requirements. Nor is it necessary to adopt legislation
that is compatible with the existing plant breeders’ rights conventions of
the Union for the Protection of New Varieties of Plants (UPOV). Once 
a country joins UPOV, it may have difficulty resisting international
pressures to strengthen the rights of commercial plant breeders. 
• Every time plant intellectual property legislation has been amended in
the industrialized world, it has extended the scope of protection and
the rights of commercial breeders, at the expense of farmers, genetic
diversity and society. Incentives for innovation in plant breeding and
new technologies need not be based on the assumption of exclusive
m o n o p o l y, as is the case with plant breeders’ rights and patents. 
• Under any intellectual property system, farmers should be guaranteed
the absolute right to save and exchange seed, and to experiment with
exotic germplasm. Any incursions into these rights will cut the heart
out of global strategies for the conservation and enhancement of agri-
cultural biodiversity. These considerations should be reflected in any
strategy by rural peoples to influence how the W TO ’s intellectual
property provisions are translated into national law. 
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Aid slighted truth, with thy persuasive strain
Teach erring man to spurn the rage of gain;
Teach him that states of native strength possessed,
Though very poor, may still be very blest …
– Oliver Goldsmith, The Deserted Village, 1770
National strategies should also be developed to: 
• ensure that Farmers’ Rights are protected nationally;
• ensure that national laws and regulations (like seed certification) do
not undermine the critical role of farmers in in situ conservation; and
• prepare and monitor national government positions in regional and
international discussions.
Regional Level Strategies
Many regional bodies, such as the Andean Pact, ASEAN in Asia, and the
Southern Africa Development Coordinating Conference (SADCC) are also
considering intellectual property. Rural communities, NGOs and peoples’
o rganizations can also influence these discussions. Those who are moni-
toring intellectual property rights should learn about the discussions that
are going on within their regions and seek appropriate ways to intervene. 
I n t e rnational Level Strategies
National and regional efforts will underpin work at the international
( i n t e r-governmental) level, where many opportunities also exist to 
i n fluence the direction of intellectual property as it relates to living
o rganisms and knowledge about them. The World Trade Org a n i z a t i o n ,
and the Convention on Biological Diversity are principal targ e t s .
Both the World Trade Organization and the Biodiversity Convention
specifically protect the intellectual property interests of the biotechnology
i n d u s t r y, the W TO by obligating signatories to pass intellectual property
legislation over life forms, and the Biodiversity Convention by stipulating
that such legislation must be respected. Farming communities are eff e c-
tively marginalized from the rewards and benefits of industrial intellectual
property systems. By strengthening the hand of the already-powerful
against the weak and by setting the rules of trading to favour industry in
the North, both the W TO and the Biodiversity Convention offer a gloss
of legitimacy to the further appropriation by Northern industry of resources
and knowledge from the South. 
The Biodiversity Convention acknowledges “communities embodying
traditional lifestyles”, yet proposes nothing to protect their intellectual
i n t e g r i t y. These inequities in the new enclosure system mean that all
countries should consider alternatives to industrial models of intellectual
p r o p e r t y. The role of innovation in society should be re-examined in a
multilateral forum before GAT T is reviewed in 1999.
On the international level, governments, rural communities, farmers,
p e o p l e s ’ o rganizations, and NGOs can influence intellectual property
discussions that are already taking place. Several important forums 
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provide the framework for a concerted international effort to reverse
global trends in intellectual property. By combining international action
in these bodies with carefully developed national strategies, farmers’
o rganizations and other activists can influence the direction of IPR. T h e y
can propose alternatives that better protect the intellectual integrity of
rural communities. 
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WORLD INTELLECTUAL PROPERTY ORGANIZATION (WIPO),
G E N E VA
WIPO has 151 member states, including all industrialized countries and
many countries of the South. The annual WIPO Council includes rep-
resentatives from member states as well as observers. Each IPR
Convention also has its own membership and forum under W I P O ,
whose Director General is usually the Secretary General of the individ-
ual conventions. Day-to-day operations are carried out by a specialist
secretariat, effectively led by a Deputy Secretary General.
S T R ATEGIC POTENTIAL Many governments are now reviewing
and/or preparing to adopt new IP legislation. Most have limited
resources to consider legislative options. Governments, regional bodies
or international agencies could ask WIPO to conduct studies, develop
new IP concepts, or prepare legislative options. Requests could also be
made to draft prototype laws concerning new areas of rights such as
F a r m e r s ’ Rights or indigenous knowledge, or areas prescribed by the
W TO such as sui generis legislation covering plants. WIPO could be
asked to apply concepts developed in its Model Law on Folklore (see
UNESCO, below) to rural community knowledge and agriculture.
UNION FOR THE PROTECTION OF NEW VARIETIES OF PLANTS
(UPOV), GENEVA
U P O V was established in 1961 to deal with plant breeders’ rights. It has
30 member governments and seven others have initiated proceedings to
join. There are two operative UPOV Conventions dated 1978 and 1991.
As of January 5th, 1996, Australia, Denmark, Israel and Slovakia had
r a t i fied the more restrictive 1991 Convention that makes plant breed-
e r s ’ rights more like patent protection and limits the right of farmers to
trade protected seeds with their neighbours. The UPOV Council meets
every October, after a series of inter-governmental and government/
industry committee meetings that regulate the Conventions’ evolution.
Many countries of the South are preparing to join UPOV.
S T R ATEGIC POTENTIAL U P O V could be asked to conduct studies,
develop new IP concepts, or prepare legislative options. Requests could
also be made to draft prototype laws concerning new areas of rights
such as Farmers’ Rights or indigenous knowledge, or areas prescribed
by the W TO such as sui generis legislation covering plants. 
UN FOOD AND AGRICULTURE ORGANIZAT I O N
• I n t e rnational Undertaking on Plant Genetic Resourc e s
• FAO Commission on Genetic Resources for Food and
Agriculture
• F a rmers’ Rights
The FA O ’s International Undertaking on Plant Genetic Resources was
signed in 1983 and is currently being revised to make it consistent with
the Biodiversity Convention. The FAO Commission on Genetic
Resources was also established in 1983 to monitor and develop policies
and programs related to plant genetic resources. The Undertaking is a
framework agreement for the collection, conservation and exchange of
plant genetic resources internationally. In 1985 the name was changed to
the International Undertaking on Plant Genetic Resources for Food and
Agriculture. In 1985 the Commission introduced the principle of
Farmers’ Rights as a counter-balance to plant breeders’ rights, and to
acknowledge farmers as past, present and future in situ agricultural
innovators and conservers, and in 1991 the Undertaking was amended to
include Farmers’ Rights. Farmers are recognized as innovators entitled
to intellectual integrity and to compensation whenever their innova-
tions are commercialized. Compensation was anticipated via a global
Gene Fund, paid into by the North for genetic conservation and
improvement in the South.
S T R ATEGIC POTENTIAL The principle of Farmers’ Rights sets a
precedent for collective rather than individual rights, but it has not yet
been implemented. No compensation mechanism has been established
and few funds have been committed to make Farmers’ Rights a reality.
It is accepted that farmers have the right to Germplasm, Information,
Funds, Technologies and Farming/Marketing Systems (GIFTS).
Agenda 21 (the action plan of the Earth Summit) and the Biodiversity
Convention have adopted the term, but must still interpret what it
means over the coming years. The government of India is drafting leg-
islation to establish Farmers’ Rights in law. Several forums, including
the FAO and the Biodiversity Convention, will discuss Farmers Rights
in the late 1990s. Rural communities and farmers’ o rganizations will
need to participate actively in these discussions if the principle is to be
translated into effective policy and practice.
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UNESCO MODEL LAW ON FOLKLORE
In the early 1980s, UNESCO and WIPO developed a Model Law on
Folklore as a new approach to intellectual property protection for
indigenous communities. It explicitly excludes science and technology
and focuses on traditional cultural activities. It does acknowledge com-
munity (not individual) inventors, and recognizes ongoing community
ownership over innovations as long as communities continue to devel-
op their cultural activity. They are assumed to have the right to fin a n-
cial benefit from their innovations.
S T R ATEGIC POTENTIAL Though developed for different purposes,
the concepts of community inventor and community ownership are
important precedents for farming communities to be aware of in the
context of IP d e b a t e s .
UNESCO INTERNATIONAL BIOETHICS COMMITTEE
In 1994 UNESCO set up an International Bioethics Committee to 
consider ethical issues related to research on the human genome. T h i s
committee solicited public opinion and drafted a report in 1995. T h e
committee is to draft an international legal instrument to govern human
genetic research in 1996.
S T R ATEGIC POTENTIAL This forum is particularly relevant for people
wishing to influence the debate about human patenting. UNESCO has
tended to be supportive of the South and of indigenous knowledge. It is
therefore a forum to monitor closely and consider using in the IP
d e b a t e .
WORLD HEALTH ORGANIZATION (WHO)
WHO takes a lead role in matters relating to medical ethics and medicinal
plants. It is governed by the World Health Assembly that takes annually
in May. 
S T R ATEGIC POTENTIAL The WHO is a logical forum in which to
raise concerns about human patenting. It is also a place where intellec-
tual property in relation to medicinal plants and knowledge can be
raised. WHO may provide medical concepts of prior informed consent
that could be adapted to deal with access to traditional seed varieties,
medicinal plants, and community knowledge about them.
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CONVENTION ON BIOLOGICAL DIVERSITY
When the Convention was adopted in May 1992, delegates identifie d
issues that needed further attention, including intellectual property rights,
F a r m e r s ’ Rights and methods of compensation, and the status of bioma-
terials collected before the Convention came into force in December
1993. The Convention held two inter-governmental meetings before the
first official Conference of the Parties (COP I), held in the Bahamas in
late 1994. COP II was in Jakarta in November 1995. COP III is scheduled
for Buenos Aires, A rgentina, in November 1996. By the end of 1995, 11 8
countries had ratified the Convention and had the right to participate in
C O P meetings. The US has not ratified the Convention, but plays a 
s i g n i ficant role from the sidelines. It is expected to join in 1997.
STRATEGIC POTENTIAL All the original outstanding issues remain
unresolved and all future COP meetings will be opportunities to influ-
ence their resolution. At COP I and II, peoples’organizations and NGOs
worked actively for recognition of Farmers’Rights, and publicized con-
cerns about biopiracy and human patenting. Human patenting was raised
formally at COP II by the governments of Papua New Guinea and the
Solomon Islands. COPIII will include a major focus on agricultural bio-
diversity and related concerns. NGOs and indigenous peoples’organiza-
tions are already developing their strategies to influence future meetings.
With an expected budget of several hundred million dollars a year, the
Convention offers a realistic opportunity for the compensation of
indigenous knowledge, inside or outside existing IP accords. 
WORLD TRADE ORGANIZATION (WTO)
The W TO was created in April 1994 at the end of the Uruguay Round
of GAT T. It became operational on January 1st, 1995 to manage and
monitor the GAT T agreement and pursue global trade objectives. It is
likely to become a dominant forum for determining the future of intel-
lectual property worldwide. All developing country governments have
at least until 2000 before they must implement the W TO ’s intellectual
property provisions. Least developed countries have until 2004. T h e
W TO ’s IPR provisions are to be fully reviewed in 1999.
S T R ATEGIC POTENTIAL The 1999 W TO review of intellectual prop-
erty is a critical target date for strategies on IP. It will be important to
monitor the implementation and review processes associated with the
Uruguay Round, and to develop strategies as appropriate. Governments
of the South should remember they can proceed slowly before imple-
menting the W TO ’s IPR provisions. They can use the leeway that exists
for IPR implementation to explore options and consider alternatives.
NGOs can bring this to the attention of their governments.
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I N T E R N ATIONAL COURT OF JUSTICE (WORLD COURT )
The World Court (The Hague, Netherlands) has existed in its present
form since 1946 as the principal legal organ of the United Nations. It
has 15 judges from different countries and legal systems, elected by the
UN. The Court decides legal disputes between states and gives advisory
opinions to specific UN agencies in accordance with international law.
Only states may be parties to disputes before the Court. Advisory 
opinions are given only to public international organizations. 
S T R ATEGIC POTENTIAL In December 1994, after an NGO-led cam-
paign, the UN General Assembly adopted a resolution asking the Wo r l d
Court for an Advisory Opinion on the legality of the threat or use of
nuclear weapons. Inspired by the nuclear weapons example, NGOs
have begun to mount a similar strategy to bring two life patenting issues
to the UN General Assembly and then to the International Court of
Justice. Both would seek an Advisory Opinion from the Court. One
would be on the morality of life patenting in general, and the patenting
of human genetic material in particular. The second would be on the
predatory nature of the W TO ’s requirement for governments to intro-
duce intellectual property laws, given their implications for sovereignty
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APPENDIX A
A Short History of the Patent System
Early History
Although monarchs sometimes granted patent monopolies as a royal privilege, until
the British Statutes of Westminster governments tended favour the right of the people
to have access to inventions over the right of inventors to have exclusivity.
480 E m p e ror Zeno of Rome rejects the concept of monopoly. 
1 4 7 4 City State of Venice establishes the first patent law, but adds the rule that a patent must be “worked”
or forf e i t e d .
1 6 2 3 English Statute of Monopolies establishes modern patent law.
1 7 9 0 – 9 4 Fledgling US government establishes patents as a constitutional right while the re v o l u t i o n a ry govern-
ment in France passes patent legislation aff i rming that an inventor has a monopoly as a “natural
right”. Austria accepts patents but describes patents as an “exception” to the natural right of citizens
to have access to inventions.
The Patent Push
With the end of the disruption caused by the Napoleonic Wars, Europe lagged
behind the United Kingdom. Believing that their lack of innovation was because 
they lacked patents, many countries scrambled to adopt British patent laws.
1 8 2 5 - 5 0 Companies press for strong patent monopolies in the UK, Germ a n y, Spain, and Switzerland. The US
Patent Office launches the first formal government expedition to collect exotic plants abroad, which
continues for almost a century.
Patent Resistance
The Dutch, Germans and Swiss, scrambling to overtake England’s technological lead,
quickly discovered that their adoption of patents reduced their access to critical
inventions and increased costs. Technology importers organized to oppose the
patent system.
1 8 5 1 - 5 3 Swiss legislature rejects another attempt to establish a patent system. British Parliament begins
investigation of complaints against patents. The concept of compulsory licensing for inventions is
raised in both the UK and Germ a n y.
1 8 6 2 - 6 5 British Parliament attacks abuses of the patent system as scientists demand c o m p u l s o ry licenses.
G e rman Congress condemns patents as “injurious to public welfare”, while German chambers of
c o m m e rce call for abolition of all patent monopolies. Swiss legislature describes the principle of
patents as “ p e rnicious and indefensible.” Scientific organizations in the UK repeat their call for com-
p u l s o ry licenses. Italy, Portugal and New Zealand adopt patent laws.
1 8 6 9 - 1 8 7 2 British House of Lords passes a bill calling for compulsory licenses and applies other tough re s t r i c t i o n s
on monopoly rights. Prominent British politicians call for abolition of patents. Dutch parliament
repeals its patent law claiming that “a good law of patents is an impossibility.” Canada and Japan 
adopt patent laws.
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“ C o m p u l s o ry” Capitulation
Faced with mounting opposition, technology-exporting countries proposed to restrict
their patent monopoly by permitting compulsory licenses to be imposed by states if
royalty rates or access were deemed to be unfair. Patent opponents accepted the
compromise. Within decades, however, the compulsory license concept was almost
universally discarded under corporate pressure.
1 8 7 3 Patent Congress at the Vienna Wo r l d ’s Fair adopts compulsory licenses as a solution to the monopoly
dispute. Opposition crumbles with the compromise. Japan repeals its patent law as a result of 
economic depre s s i o n .
1 8 7 4 - 7 7 Patent re f o rm bill passed in the British House of Lords is withdrawn in the House of Commons.
Germany adopts a new patent law. Switzerland continues to re s i s t .
1 8 8 3 Paris Union establishes an international patent re g i m e .
1 8 8 5 - 1 9 0 0 “Industrial pro p e rty” is defined to include agricultural products including grain, fruit, and cattle. In the
following years, Norw a y, Denmark and Finland adopt patent laws while Japan re - i n t roduces its sus-
pended law. Switzerland finally capitulates to international pre s s u re but still excludes chemicals and
textiles from patentability.
1 9 0 3 - 1 0 The Netherlands re - i n t roduces patents and Australia adopts a patent law. Under p re s s u re fro m
G e rm a n y, Switzerland capitulates on chemicals and textiles .
Early Moves to Patent Life
Louis Pasteur had been granted a patent on a microorganism and French rose
breeders wanted the same right. Ornamental breeders got their wish by arguing 
they would never patent food crops.
1 9 2 2 G e rman Supreme Court upholds a process patent on a bacterium derived from a turtle, useful in
t u b e rculosis treatment. London meeting of industrial patent lawyers discusses need for protection 
of plant varieties.
1 9 3 0 US Congress passes a unique Plant Patent Act allowing the monopolization of asexually produced
fruits, trees and ornamentals. Potatoes and other asexually p roduced vegetables are excluded.
1 9 3 4 Paris Union is amended in London and “industrial pro p e rty” definition is broadened to include 
“ flowers and flo u r ” .
1 9 4 8 Italian High Court declares plants patentable, but legal confusion leads to a call for special plant
variety law.
1 9 5 2 Vienna session of the International Association for the Protection of Industrial Pro p e rty fails to act on
G e rman proposal on plant bre e d i n g .
1 9 5 7 In Paris, the International Association of Plant Breeders for the Protection of Plant Varieties accepts a
F rench invitation to host a conference on plant breeders’ rights, to circumvent apathy in the industrial
patent system.
1 9 5 9 New breeds of agricultural animals and some industrial plants are declared subject to cert i ficates of
invention in the USSR.
1 9 6 1 The International Union for the Protection of New Varieties of Plants (UPOV) is established in Paris.
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New Era of Reform Arises
Mid-century reviews by American, British, and Canadian governments all cast serious
doubt on the efficiency and equability of patents. Led by UNCTAD, the South joined
the debate, expressing the same concerns as the Swiss, Germans and Dutch a 
c e ntury earlier. Some industrialized country importers of technology sided with 
the South until politicians were pressured to change their minds.
1 9 5 8 - 6 2 Fritz Matchlup’s study for the US Senate gives a landmark position rejecting the “natural right” concept
for patenting. Seymour Melman’s study for the same body claims that innovation would continue in
public and private sectors “with or without a patent system.” Canada’s Isley Royal Commission affirms
Matchlup’s view that there is no economic evidence that the patent system is justifiable, adding t h a t
patents should not be extended to plants. The Rahl study of the patent system notes: “It is not freedom
of competition which re q u i res apology. It is interf e rence with freedom which must always be explained.”
Brazil challenges the fairness of the Paris Union in the United Nations General Assembly.
1 9 6 7 The Banks Committee in the UK aff i rms the value of patents through an “innocence by association”
a rgument that patents and industrial development appear to share a common history. The Committee
concedes that no empirical data exists on the merits of patents. Paris Union is amended and 
s t rengthened in Stockholm.
1 9 7 4 U N C TAD study rejects the “natural right” concept. Fur-bearing animals become subject to cert i fic a t e s
of invention in the Soviet Union.
1 9 7 6 - 8 0 Canadian Working Paper on Patent Law Revision rejects the validity of the patent system for a new 
act with a “sunset clause”. Canada, Spain, Ireland and G reece oppose the patent system and align
themselves with the Group of 77 at a critical Nairobi Conference. Shortly after, Canadian officials 
a re removed or replaced, and a pro-patent policy is adopted by govern m e n t .
1 9 8 2 U N C TAD Trade and Development Board vigorously attacks its Secre t a r i a t ’s eff o rts to re f o rm the patent
system, led by British and American diplomats. UNCTAD initiative grinds to a halt.
Back to Life
Patents for ornamental plants quickly grew to become plant b r e e d e r s ’ rights for food
crops. Compulsory licenses were history and the push was on to permit the patenting
of all living things.
1 9 6 9 In the landmark Red Dove decision, German Federal Supreme Court rules that a process for bre e d i n g
animals may be patentable. New Hungarian patent law expressly permits the patenting of animal
b reeds under criteria similar to UPOV ru l e s .
1 9 7 0 In Washington, 35 countries sign the Patent Cooperation Treaty to ease the patent application work of
companies by adopting a more uniform approach among industrialized states. The US Plant Va r i e t y
P rotection Act is passed during the Christmas season of a dying Congress. For the first time cere a l s
and vegetables are patentable. 
1972 & ’78 UPOV Convention is stre n g t h e n e d .
1 9 7 5 M i c ro o rganisms are ruled patentable in German Bakers’ Yeast case.
1 9 8 0 In a five to four decision, the US Supreme Court allows General Electric to obtain a patent on a
m i c ro o rganism under regular industrial (“utility”) patent law. In another Christmas battle, the US
C o n g ress amends the 1970 Act to include six major vegetables previously excluded. 
1 9 8 0 - 1 9 8 4 American patent applications by publicly-funded universities and hospitals for inventions containing
human biological material increase by more than 300%. American doctors for leukemia patient John
M o o re receive a patent on a cell line derived from his cancerous spleen which produces high levels of
useful and pro fitable proteins. Moore files a lawsuit claiming his blood cells were misappropriated and
demanding a share in the potentially multi-billion dollar pro fits derived from use of these cells.
1 9 8 5 US Patent Office rules that plants can be patented under industrial patent laws.
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1 9 8 7 US Patent Office announces it will allow industrial patenting of higher life forms, including pets and
livestock. A patent official leaves open the possibility of patenting human “traits”. Genome Inc.
announces it will try to copyright the base pairs of the human genome.
1 9 8 8 US Patent Commissioner reveals a new policy allowing livestock patent holders to charge royalties on
the offspring for the patent’s duration. DuPont obtains an American patent on the first transgenic mouse
( c reated with human genes), genetically engineered for its susceptibility to cancer. A Commission of the
E u ropean Community drafts a decree on the “legal protection of biotechnological inventions” that would
go beyond US decisions, making patents on all life forms possible (including progeny of patented
plants or animals). The proposal would reverse the burden of proof, to better protect inventors from
infringement.
1 9 9 0 C a l i f o rnia Supreme Court rules that John Moore (from his 1984 case) had no rights of ownership
over his cells after they were removed from his body, but has the right to sue his doctors for failing 
to inform him of the potential commercial value of his cell line. 
1 9 9 1 UPOV revises its 1978 Convention, to extend the protection granted to corporations and reduce the
rights of farmers. It includes clauses on essentially derived varieties.
1 9 9 2 The legally binding International Convention on Biological Diversity is signed in Brazil aff i rming the
legitimacy of intellectual pro p e rty over life forms. The US National Institutes of Health files for patents
on thousands of gene sequences related to the human brain whose function is not yet known, sparking
worldwide protest. Nobel Laureate James Watson describes the patent application as “sheer lunacy”.
US Patent Office grants two patents to W.R Grace subsidiary Agracetus for all genetically engineere d
c o t t o n .
The Years of Living Dangero u s l y
As GATT entrenches life patenting, Cargill’s offices in India are burned down and
patents are granted on entire crop species in Europe and the United States. Other
patents are granted on human cell lines over the protest of religious leaders. The
debate could go either way. Ownership of life is in the balance.
1 9 9 3 Mass protests and riots erupt in India as farmers become aware of the impending impact of GATT 
on the ownership of life forms. Brazilian farmers, indigenous peoples and religious leaders org a n i z e
against American pre s s u re to toughen patent laws in that country. An American government attempt
to patent the cell line of a Guaymi woman in Panama is blocked by indigenous peoples’ org a n i z a t i o n s .
1 9 9 4 G ATT Uruguay Round is concluded. For the first time intellectual pro p e rty is considered a trade issue,
g o v e rned by the World Trade Organization. Signatory states are re q u i red to provide for patents on
m i c ro o rganisms and some kind of IPR coverage for plants. The European patent office grants
A g r a c e t u s / W.R. Grace a patent on all genetically engineered soybeans. After public and industry
p rotest, the US Patent Office revokes two Agracetus patents on all genetically engineered cotton
(though the patent remains valid until all avenues of appeal are exhausted). The Prime Minister of
India announces India will withdraw species patents on cotton.
1 9 9 5 The US Supreme Court interprets “farmer exemption” narro w l y, to limit the amount of pro p r i e t a ry
seed which can be saved and possibly sold by farmers. In a landmark decision, the European Parliament
rejects legislation that would remove all barriers to life patenting in the European Union. An intern a-
tional meeting of leading human genome scientists concludes that the patent system is the “mecha-
nism of excellence” for commercializing the results of the Human Genome Project. Eighty American
religious leaders from all major faiths issue a statement opposing patents on human and animal
genes as a violation of the sanctity of life. Led by Third World Network, an international campaign
against patents on the neem tree is launched. European Patent Office concurs with Greenpeace that
plant variety patents are not acceptable. US government grants itself a patent on the cell line of a
Hagahai man in Papua New Guinea and awaits a second patent on the cell line of an indigenous person
in Solomon Islands. Pacific Island governments, Canada and Sweden protest at the Biodiversity
Convention. 
Sources: The Laws of Life: Another Development and the New Biotechnologies(Dag Hammerskjold Foundation, 1988); 
RAFI Communiqués; scientific and trade journals; 
Neil Hamilton, Possible Effects of Recent Developments in Plant Related Intellectual Property Rights in the US,(1995). 
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T R A N S N ATIONAL ENTERPRISES
Enterprises have contractual arrangements to ensure that named inventor(s)
s u rrender all or most of their rights to the company.
Enterprises generally invent to improve their own production and/or market,
and secondarily to license their invention to competitors.
Enterprises generally deal with micro - i m p rovements, and find these patent 
criteria difficult but manageable.
Enterprises have scientific personnel, laboratories and experience to meet
technical demands easily.
Enterprises have in-house legal departments and ready access to specialist
c o n s u l t a n t s .
Enterprises have no problem with high fees.
Enterprises usually apply for patents in every feasible country, often applying
in more countries than necessary.
Enterprises meet this obligation ro u t i n e l y.
Enterprises often establish a number of related patents (“patent families”) to
p revent full disclosure and maximize their opportunity for pro f i t .
Enterprises make use of this “re s e a rch exemption” to invent around patented
i d e a s .
Enterprises have no difficulty financing or administering their patents thro u g h
their legal depart m e n t s .
Enterprises tend to “cross-license” to one another across diff e rent industries
and geographic markets. Those unable to offer multi-technology and 
multi-market opportunities will benefit less.
Enterprises are often aggressive in defending patents and using patent claims
as a means of declaring their market turf .
I S S U E
Inventor: In Intellectual Pro p e rty (IP) law, an inventor is a named individual or
a group of named individuals.
I n v e n t i o n : With exceptions, most patentable inventions are highly specific
m i c ro - i m p rovements that may have macro - a p p l i c a t i o n s .
R e q u i rements: In most IP systems, criteria for patents include: 1) stand a rds of
consistency (uniformity and stability over time); 2) non-obviousness or novelty;
and 3) creativity (evidence of an “inventive step”). 
P reparation: Isolation, purification and description of biomaterial in a 
technically arduous manner is critical to the success of the patent application.
Cost of Advice: Advice from highly-specialized patent lawyers on biomaterials
costs from US$20,000 to US$40,000 in diff e rent jurisdictions.
Cost of Applications: F o rms are complex and fees vary among countries.
Fees can range from a few hundred to a few thousand dollars.
Coverage: There are no universal patents. Generally, biomaterials are patented
in the US, Europe and Japan. It is entirely legal to exploit someone else’s patent
in a country that does not register the patent.
Deposit: U s u a l l y, biomaterials under patent claim must be deposited in an
institution designated by the patent office. At the American Type Culture
Collection, the annual cost of deposit is about US$500.
D i s c l o s u re: To obtain a patent, the inventor must disclose the full invention
so that others can duplicate the process or re s u l t s .
Exemption: In order to encourage scientific investigation, IP laws encourage
access to patented technologies for basic re s e a rch. 
Maintenance: Usually patents lapse if maintenance fees are not paid annually.
Fees generally rise as the patent ages. It is estimated to cost US$250,000 to
e n f o rce a patent over its life span.
Licensing: Strategies for licensing patents to others are central to the 
e ffective maximization of patent benefit s .
Infringement: Intellectual pro p e rty falls under civil not criminal law. It is up
to patent holders to police and defend their patents, which can be extre m e l y
expensive and time consuming. If patent holders cannot defend their patents,
others will breach them with impunity.
APPENDIX B
Who Has Access to We s t e rn Intellectual Pro p e rty Systems? 




IP law does not recognize community invention. The concept of an individual
inventor is sometimes alien to communities, and can cause diff i c u l t i e s .
Communities often develop complex macro-technology inventions that may
apply only in micro-markets, or in situations highly specific to the community.
This makes patenting more pro b l e m a t i c .
Since these criteria have little or nothing to do with the actual use of an 
invention, communities will probably find the criteria difficult to meet.
Community expertise and experience is radically diff e rent from the technical
re q u i rements for patent claims. They generally have to trust or pay others to
do this work.
Communities cannot usually aff o rd or obtain either basic or specialist legal
a d v i c e .
Communities may find most application fees too expensive, since they must
be paid in advance of any anticipated ro y a l t i e s .
Communities find it difficult to manage multi-state patents, for language and
financial re a s o n s .
Communities may be concerned that a deposit could lead to a misuse of their
invention. Communities may also find the cost high.
Communities risk exposing their macro-innovation in one patent, and then
find it the subject of numerous micro-patent claims by others.
Communities generally view themselves as sellers and not buyers of 
inventions. Research exemptions strengthen the hand of buyers over sellers.
Communities can encounter language and cost problems in administering
patents from year to year. 
Communities find it difficult to judge the fairness of licensing proposals and
will not be able to offer patent trades with prospective part n e r s .
Communities find it almost impossible to monitor and confront patent
infringements around the world.
PUBLIC SECTOR INSTITUTES
Institutes can have similar arrangements with their re s e a rch scientists,
depending on their arrangements with govern m e n t s .
Institutes tend to have less targeted re s e a rch goals. The products of their 
discoveries are not usually as patentable.
Institutes, for reasons of experience and funding, are often less able to 
manage these criteria.
Institutes may or may not have the necessary personnel and equipment. Many
institutes lack experience.
Institutes generally have little in-house legal capacity, and limited access to
inexpensive legal expert i s e .
Institutes may find application fees onero u s .
Institutes often make the mistake of patenting only in their own country, or in
one of the major markets. An interested competitor could exploit the institute’s
invention from a country that does not honour the patent. 
Institutes can usually meet this obligation, though cost is often a consideration.
Institutes dedicated to public scientific exchange generally make full disclosure
in one patent claim, exposing themselves to imitation.
Institutes often find that others are inventing around their patented inventions,
while they are enjoined by enterprises not to infringe on company claims.
Inexperienced public institutes may allow patents to lapse because of 
administrative oversight or cost concern s .
Institutes often operate in a single industry segment and have a limited capacity
to negotiate with counterparts in other parts of the world.
Institutes tend not to have a strong patent defense and sometimes accede to
political pre s s u re not to challenge the private sector.
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APPENDIX C
Bioprospecting and Biopiracy Activities
C o m p a n y / O rg a n i z a t i o n
Abbott Laboratories ( U S A )
A d h e ron Corporation ( U S A )
American Cyanamid ( U S A )
AMRAD Corporation (Australian Medical R and D)
AMRAD Corporation ( A u s t r a l i a )
AMRAD Corporation ( A u s t r a l i a )
Aphios Corporation ( U S A )
Boehringer Ingelheim ( G e rm a n y )
Bristol-Myers Squibb ( U S A )
Bristol-Myers Squibb ( U S A )
Bristol-Myers Squibb ( U S A )
Bristol-Myers Squibb ( U S A )
Caapi Associates ( U S A )
Ecogen Incorporated ( U S A )
E c o p h a rm (USA – division of Pharm a g e n e s i s )
Ecoscience Corporation ( U S A )
Eli Lilly Co. ( U S A )
Ethno-Medicine Pre s e rvation Project ( P e ru )
Foundation for Ethnobiology ( U K )
Glaxo Group ( U K )
Instituto Nacional de Biodiversidad – InBio
(Costa Rica)
What Collecting?
m i c robes, plants
marine bacteria and other org a n i s m s
arid land plants for crop protection agents and
p h a rmaceutical development
d rug discoveries from marine org a n i s m s
d rug discoveries from marine organisms and
m i c robial soil sourc e s
Australian Aboriginal bush medicines, micro b i a l
and soil samples from Bathhurst and Melville
I s l a n d s
marine micro o rg a n i s m s
plants, micro b e s
insects and related species
r a i n f o rest plants with medicinal pro p e rties, espe-
cially Ancistrociadus (source of anti-HIV agent)
and anti-malarials
fungi, microbes, plants, marine org a n i s m s
r a i n f o rest plants for drug development, plus non-
medicinal plants for sustainable commercial har-
v e s t
Amazonian medicinal plants
entomoparasitic nematodes for biocontrol agents
m i c ro o rganisms associated with medicinal plants
s c reening of soil samples for fungal strains to be
used in pest contro l
plants, algae
p l a n t s
medicinal plants worldwide, drug and agricultural
a p p l i c a t i o n s
plants, fungi, microbes, marine org a n i s m s




A n t a rc t i c a
Australia, South East Asia
US territorial waters
D ry tropical forests of Guanacaste Conserv a t i o n
A rea in Costa Rica.
C a m e roon (Korup forest range) and Nigeria
(Oban Hills rainfore s t )
S u r i n a m e
B r a z i l
M a l a y s i a
w o r l d w i d e
C h i n a
P e ruvian Amazon
South America, Asia
Asia, Latin America, possibly other are a s
Guanacaste Park and other protected areas in
Costa Rica
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Use of Indigenous Knowledge/Indigenous Peoples or Te rr i t o r i e s
Priority given to plants with rich ethnobotanical backgro u n d .
Special focus on organisms from harsh enviro n m e n t s .
Ta rgets plant medicines used by Australian indigenous people, specifically
anti-viral, immunomodulatory, and anti-cancer compounds.
Ethnobotanical information from traditional medical practices will be used to
prioritize collection of plants.
Ethnobotanical uses of plants by indigenous peoples to be documented.
Te rms of benefit-sharing agreement not public. Conservation Intern a t i o n a l
will set up Shaman’s Apprentice pro g r a m .
P r i m a ry focus to collect medicinal plants and provide work for the poor,
p resumably drawing upon indigenous people for both identification and
l a b o u r.
Seeks out “new and important weapons in the age-old battle against 
disease” by working with traditional healers.
Specifically targets indigenous peoples’ knowledge, including Surinamese
people and Karen people in Thailand.
Possibly collecting in Talamanca Indian re s e rve, but it is unclear to what
extent infomation is obtained from indigenous peoples.
Additional Information and/or Interm e d i a ry 
P rogram re p o rtedly terminated in 1995.
US$5 million re s e a rch agreement with University of Mary l a n d .
ICBG agreement with University of Arizona, Institute of Biological Resourc e s
of Buenos Aires, National University of Patagonia, Catholic University of Chile,
National University of Mexico, Purdue University, Louisiana State University.
Collaborating with Australian Institute of Marine Science to provide AMRAD
with 20,000 samples over the next five years.
Collaborating with Antarctic Cooperative Research Centre (Hobart, Ta s m a n i a ) .
Special focus on organisms from harsh enviro n m e n t s .
Deal signed with the (Aboriginal) Nort h e rn Land Council to pay US$12–$15
per sample and undisclosed royalties if drugs are developed. Agreement with
US-based Panlabs Inc.
R e s e a rch agreements with Bristol Myers Squibb (USA), Harbor Branch
Oceanographic Institute, and CalBioMarine Te c h n o l o g i e s .
A g reements with University of Illinois and New York Botanical Garden to
obtain plants.
US government supported ICBG agreement with National Biodiversity
Institute (InBio) of Costa Rica and University of Costa Rica.
US govern m e n t - s u p p o rted ICBG agreements must include benefit sharing
with source countries, but terms are not available to the public. Also part i c i p a t i n g :
Walter Reed Army Institute of Research (US government), Smithsonian
Insitution, University of Yaounde, World Wildlife Fund, Nature Conserv a n c y,
World Resources Institute, Shaman Pharm a c e u t i c a l s .
Ranked second largest US pharmaceutical corporation. Contracts with third
p a rties to collect specimens, including Scripps Institute and Oncogen.
U S - g o v e rnment supported ICBG project with Vi rginia Technical University,
Missouri Botanical Garden, National Herbarium of Suriname, Bedrijf
Geneesmiddelen & Conservation International. Indigenous Peoples’ Fund
receives benefits, but is largely non-indigenous.
Claims that its marketing of plant extracts may solve Brazil’s financial tro u b l e s ,
deter mining, help teach the Brazilian government the value of its re s o u rc e s ,
and prevent the destruction of the Amazon.
R e s e a rch and development agreement with Malaysian Research and
Development Institute.
E x p l o res potential pharmaceutical leads from nonpathogenic microbes living
in mutually beneficial relationships with medicinal plants.
Ecosicence will pay Chinese Institute of Biological Contro l .
Major pharmaceutical corporation that has recently purchased Sphinx
P h a rm a c e u t i c a l s .
Aims to pre s e rve knowledge by encouraging a new generation of healers.
The Foundation purports to be an academic endeavor. Its president holds two
patents on drugs isolated from Amazonian medicinal plants. Works with 
companies with financial interests in plant re s o u rc e s .
Has obtained materials from Kew Royal Botanical Gardens, Biotics Ltd.,
University of Illinois, National Cancer Institute. Contracts with Carn i v o re
P re s e rvation Trust to collect plants in Laos.
Private organization that has entered into high profile contracts with Merc k ,
Bristol Myers Squibb, and possibly other major pharmaceutical companies.
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C o m p a n y / O rganization – cont.
I n t e rnational Marine Biodiversity Development
C o r p o r a t i o n
I n t e rnational Plant Medicine Corporation ( U S A )
I n t e rnational Organization for Chemical Sciences
in Development (IOCD – chart e red in Belgium)
Ix Chel Tropical Research Foundation (Belize)
Johnson & Johnson ( U S A )
Knowledge Recovery Foundation Intern a t i o n a l
( U S A )
Magainin Pharmaceuticals ( U S A )
Marine Biotechnology Institute ( J a p a n )
M a rtek Biosciences Corporation ( U S A )
Maxus Ecuador Incorporated ( p a rt of Maxus Petro l e u m -
USA and owned by YPF-Arg e n t i n a )
M e rck and Co. ( U S A )
Missouri Botanical Gardens ( U S A )
Monsanto Corporation ( U S A )
Myco Pharmaceuticals ( U S A )
National Cancer Institute (USA government agency)
New York Botanical Garden ( U S A )
NPS Pharmaceuticals Incorporated
Oceanix Biosciences Corporation ( U S A )
Paracelsian Incorporated ( U S A )
Pfizer Incorporated ( U S A )
Pfizer Incorporated ( U S A )
Pfizer Incorporated ( U S A )
P h a rmacognetics ( U S A )
What Collecting? – cont.
deep ocean re s e a rch to collect exotic species for
biotech applications
Amazonian medicinal plants
“ r a re trees, bushes, insects, amphibians, fungi,
m i c robes, and other natural species”
p l a n t s
novel chemical compounds
P roposal to gather and analyze indigenous
knowledge to explore the potential for developing
new dru g s .
African reptiles, marine fish & org a n i s m s
marine org a n i s m s
m i c roalgal strains for developing nutritional,
p h a rmaceutical, and diagnostic pro d u c t s
1200 plant species have been gathered, of which
18 are new to scientific world and 200 are new
species in Ecuador.
fungi, microbes, marine organisms, plants
plants (extremely large scale)
p l a n t s
s c reening of fungi for drug development
Plants, microbes, marine organisms. NCI’s natur-
al products re p o s i t o ry contains over 500,000
samples collected primarily in Africa, Asia and
Latin America.
e v e ry t h i n g
Animals, insects (especially spider and scorpion
t o x i n s )
enzymes from marine sourc e s
p l a n t s
p l a n t s
p l a n t s
p l a n t s
natural products for drug development
Geographic Location – cont.
i n t e rnational waters
E c u a d o r
Plans to start work in Africa or Latin America,
and then move worldwide.
B e l i z e
Amazon Basin region, Tropical Asia
M i c ro n e s i a
w o r l d w i d e
E c u a d o rean Amazon
Latin America
worldwide, especially tro p i c s
P e ruvian Amazon
w o r l d w i d e
w o r l d w i d e
worldwide, special focus on Latin America
M a d a g a s c a r
deep sea thermal vents, polar waters
C h i n a
U S A
Ecuador (pro p o s e d )
C h i n a
Latin America
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Use of Indigenous Knowledge/Indigenous Peoples or Te rritories – cont.
Ta rgets indigenous peoples’ knowledge of medicinal plants, and seeks to
obtain Tagaeri plant knowledge.
Will depend on indigenous people for leads and promises to deal with them
“equitably and ethically” by mobilizing local capital to “sustain biopro s p e c t-
ing at a commercial scale”.
E x p o rts samples of plants identified by traditional healers. Has export e d
1,500 such plants.
Plant collection and inventory traverses Yasuní National Park and Wa o r a n i
Ethnic Reserv e .
Indigenous knowledge from Urueu-wau-wau of Brazil. Merck holds a patent
on anti-coagulant derived from their plant material.
Does not officially emphasize indigenous knowledge, but indigenous people
used to assist its work. Collaborates with ethnobotanists as well as loggers
and oil companies.
Exclusive focus on indigenous peoples’ medicinal plants.
Uses indigenous knowledge to identify some materials.
Leading centre for ethnopharmacology and ethnobotany re s e a rch, uses
indigenous knowledge to collect.
Exclusive focus on traditional medicines.
Collections based partly on existing ethnobotanical leads.
May use indigenous people as “parataxonomists” to assist plant collection
and identification.
Exclusive focus on traditional medicines.
Company hopes to rely entirely on leads from indigenous peoples in 
identifying plants and is interested in developing a line of cosmetics 
based on indigenous peoples’ products and uses.
Additional Information and/or Interm e d i a ry – cont.
Ten year re s e a rch project undertaken with Russian Academy of Sciences.
Has proposed to forcibly extract medicinal plant information from indigenous
p e o p l e .
Says it “is working to establish the Biotic Exploration Fund, a new world-level
agency that aims to catalyze a great increase in the quantity of biopro s p e c t i n g
in developing countries.” Claims marketing samples will be motor of local
development beneficial to indigenous people.
P a rticipant in US National Cancer Institute’s phytomedical screening pro g r a m .
NCI discoveries are transferred to US companies where they may become
patented pharmaceuticals. 
Funds chemical prospecting at Cornell University and trains scientists fro m
the South in biopro s p e c t i n g .
P roposes to develop a well-documented, well-pre s e rved library of plant
extracts that can be “rented” to pharmaceutical firm s .
Developing human pharmaceuticals from African clawed frog and antibiotic
s t e roid from dogfish shark.
C o n s o rtium of Japanese government and 21 Japanese corporations.
M e rck and Co. will screen extracts from Mart e k ’s collection of more than
1600 microalgal samples. Merck pays Martek to supply extracts.
Contracts with Missouri Botanical Garden for plant collection and inventory
during construction of 120 km road in tropical moist fore s t .
Major pharmaceutical corporation. Has contracts with N.Y. Botanical Gard e n ,
M Y C O S e a rch, Martek Biosciences, including a high-profile contract with
InBio of Costa Rica involving an up-front payment of US$1.2 million.
One of the world’s largest collectors of plants. Does not conduct its own
p roduct-oriented re s e a rch, but assists and provides plant samples to
re s e a rc h e r s .
Plans to receive 1,000 samples with accompanying ethnobotanical inform a t i o n
via Washington University (St. Louis, USA) as part of US govern m e n t -
s p o n s o red ICBG-Peru program. Local indigenous peoples’ org a n i z a t i o n
opposes the pro j e c t .
Company will identify, develop and commercialize drug leads, and is also
developing screening technologies.
Contracts with University of Illinois to collect in Southeast Asia, Missouri
Botanical Garden to collect in Africa, and N.Y. Botanical Garden to collect in
Latin America. Marine organisms collected by Coral Reef Researc h
Foundation in Indo-Pacific. Microbes collected by various org a n i z a t i o n s .
Contracts with many private companies for collection of biomaterials.
Personnel prominent in the field.
Malagasy government has given NPS exclusive rights to re s e a rch animal
re s o u rces for medical uses.
Has joint re s e a rch agreement with University of Maryland. Seeks a variety of
exotic enzymes, including treatments for central nervous system diseases.
Company is seeking US government approval for anti-HIV drug derived fro m
Chinese medicine, and is iscreening at least 2,800 samples of traditional
Chinese medicines.
T h ree year, US$2 million re s e a rch collaboration with N.Y. Botanical Gard e n s .
Company proposed to pay US$1 million to receive a comprehensive set of
samples from each of Ecuador’s major biomes and their exclusive rights.
E c u a d o rean government rejected Pfizer’s pro p o s a l .
Has agreement with Academy of Traditional Chinese Medicine in Beijing to
study traditional herbs as sources of potential new drugs for human and 
animal health.
Company founded 1993 and partly owned by Pan American Development
Foundation, a non-profit organization that works with rural and indigenous
g roups. Will use these connections to organize plant collection and 
i d e n t i f i c a t i o n .
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C o m p a n y / O rganization -cont.-
P h a rmagenesis ( U S A )
P h a rmaMar ( S p a i n )
Phytera Incorporated ( U S A )
Phyton Catalytic Incorporated ( U S A )
P h y t o P h a rmaceuticals Corporation ( s u b s i d i a ry of
Escagenetics Incorporated, USA)
R e s e a rch Corporation Technologies ( U S A )
Rhone-Poulenc Rorer ( F r a n c e )
Sabinsa Corporation ( U S A )
Shaman Pharmaceuticals ( U S A )
SmithKline Beecham ( U S A )
Sphinx Pharmaceuticals ( s u b s i d i a ry of Eli Lilly, USA)
Sterling Wi n t h rop ( U S A )
Syntex Laboratories
University of Utah ( U S A )
Upjohn Company ( U S A )
Xenova Limited ( U K )
What Collecting? -cont.-
p l a n t s
bioactive materials from marine sources to
develop drugs for cancer and AIDS
p l a n t s
p l a n t s
p l a n t s
b a c t e r i a
m i c robes, plants, marine org a n i s m s
p l a n t s
plants for drug development
m i c robes, plants, marine org a n i s m s
fungi, algae, plants, marine org a n i s m s
m i c robes, plants, marine org a n i s m s
m i c robes, plants
p l a n t s
m i c robes, plants
m i c ro o rganisms and plants
Geographic Location -cont.-
A s i a
w o r l d w i d e
w o r l d w i d e
Africa, Asia, Europe, Americas
negotiating agreements with groups in Africa,
Brazil, China, India, Eastern Europe 
Latin America
I n d i a
Latin America, Africa, Asia
P a n a m á
w o r l d w i d e
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Note: Initial incarnations of this list compiled by RAFI with assistance from Jack Kloppenburg, GRAIN, Accis.
Use of Indigenous Knowledge/Indigenous Peoples or Te rritories -cont.-
Focus on traditional medicinal plants, especially Chinese.
Focus on plants with established medicinal uses in Indian culture s .
S h a m a n ’s strategy is to identify promising plants by using indigenous
knowledge, with traditional healers as primary informants. Shaman has 
n o n - p rofit Healing Forest Conservancy to facilitate re c i p rocal flow of 
benefits and support conservation. 
Plans to target plant knowledge of the Emberá people and farmers. Claims
that drug finds will make indigenous people “more likely to value the fore s t ” .
Additional Information and/or Interm e d i a ry -cont.-
P h a rmaMar re s e a rchers travel aboard the ships of Pescanova, one of the
l a rgest fishing fleets in the world. 
Specializes in plant cell technology and holds one of world’s largest plant cell
collections. Uses technology to provide large quantities of a compound fro m
small tissue samples.
Focuses on production and supply of plant-derived compounds through cell
c u l t u re. 
Will acquire plant samples from collaborating institutes that will retain rights
on drugs developed from plant materials and receive royalties. Filed for 
b a n k ru p t c y in January, 1996.
B rokering bacteria with nematocidal and antifungal pro p e rties isolated fro m
Costa Rican soil sample.
Samples obtained from University of Hawaii, Shanghai Medical University,
Beijing Medical University, and Tianjin Plant Institute.
New company hopes to introduce and broker botanical and pharm a c o l o g i c a l
re s o u rces of India in North America. Will develop, process and market 
s t a n d a rdized extracts of Indian plant materials.
Shaman has had remarkable success in identifying potentially valuable dru g
leads based on indigenous knowledge. Has received two patents on drugs in
clinical trials (anti-fungal and anti-viral). Strategic alliances with Eli Lilly,
M e rck, Bayer, and Inverni della Beffa of Italy. 
In-house collectors, but also obtains materials through Biotics, Kew Royal
Botanical Gardens, University of Vi rginia, Scripps Institute of Oceanography,
M o rris Arboretum, and MYCOsearc h .
Has obtained materials from Biotics.
Has obtained materials though Mississippi State University, Brigham Yo u n g
U n i v e r s i t y, and N.Y. Botanical Gard e n .
Has obtained materials from the Chinese Academy of Sciences.
P roposed project with the University of Panamá, Smithsonian Tro p i c a l
R e s e a rch Institute, Natura Foundation, and an unidentified “indigenous 
o rganization”. No concrete plans for compensating local people.
Major pharmaceutical corporation. Has obtained materials through the
Shangai Institute.
Company has collection of 23,000 live micro o rganisms (lichen, bacteria,
fungi), both in-house and in labs of collaborators. Alliances with Genentech,
Wa rn e r- L a m b e rt Company, Genzyme and Suntory Limited, and other academic




Leading Enterprises in Five Major Life Industry Segments
World’s Top 10 Agrochemical Corporations
C o m p a n y H e a d q u a rt e r s 1995 Sales (US) C o m m e n t
N o v a rtis S w i t z e r l a n d 4,410 million combined Ciba Geigy and Sandoz
M o n s a n t o U S A 2,472 million
B a y e r G e rm a n y 2,373 million
Z e n e c a U K 2,363 million
A g r E v o G e rm a n y 2,344 million f o rmerly Hoechst and Schering
Du Pont U S A 2,322 million
R h o n e - P o u l e n c F r a n c e 2,068 million
D o w E l a n c o U S A 1,962 million
American Home Pro d u c t s /
American Cyanamid U S A 1,910 million American Home Products acquired American
Cyanamid 
B A S F G e rm a n y 1,450 million
Source: RAFI, based on AGROW, No. 253, March 29, 1996.
The top 10 agrochemical corporations accounted for $23.6 billion, or 81% of all agrochemical sales in 1995.
World’s Top 10 Seed Corporations
C o m p a n y H e a d q u a rt e r s Estimated Sales (US) C o m m e n t
Pioneer Hi-Bred Intl. U S A 1, 500 million
N o v a rt i s S w i t z e r l a n d 900 million f o rmerly Ciba Geigy and Sandoz
L i m a g r a i n F r a n c e 525 million F rench cooperative
S e m i n i s M e x i c o 500 million owned by Empresas La Moderna (Mexico) and 
G e o rge J. Ball (USA) 
Z e n e c a / Van der Have The Netherlands 460 million pending merg e r
Ta k i i J a p a n 450 million vegetable/flower/maize/ turf g r a s s
Dekalb Plant Genetics U S A 320 million Monsanto is a large shareholder (approx. 40%)
K W S G e rm a n y 315 million
S a k a t a J a p a n 300 million v e g e t a b l e / f l o w e r / t u rf g r a s s
C a rg i l l U S A 250 million p r i v a t e l y - h e l d
Source: RAFI, based on information provided by Kent Group Inc.
The commercial seed industry is worth approximately (US) $15 billion per annum. The top 10 corporations account for $5,520 billion,
or 37% of the worldwide market.
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RAFI estimates that the total world pharmaceutical market is approximately $197 billion per annum. The top
10 companies account for approximately 43% of the total.
World’s Top 10 
Food and Beverage Corporations
C o r p o r a t i o n H e a d q u a rt e r s 1995 annual sales food & drink as % 
(food and drink) of total sales
US$ millions
Nestle SA S w i t z e r l a n d $ 4 6 , 4 0 0 9 9 %
Philip Morris Inc. U S A $ 3 3 , 0 3 5 5 0 %
Unilever PLC/NV U K / N e t h e r l a n d s $ 2 5 , 3 0 0 5 6 %
ConAgra, Inc. U S A $ 2 0 , 3 4 5 8 4 %
Coca-Cola Co. U S A $ 1 8 , 0 1 8 1 0 0 %
PepsiCo Inc. U S A $ 1 6 , 1 2 3 5 3 %
Mars Inc. U S A $ 1 3 , 5 0 0 1 0 0 %
C a rgill Inc. U S A $ 1 2 , 9 2 9 2 8 %
A rcher Daniels Midland U S A $ 1 2 , 6 7 2 1 0 0 %
Kirin Bre w e ry Co. J a p a n $ 1 2 , 6 2 6 9 7 %
Source: DataMonitor
World’s Top 10 
Pharmaceutical Corporations
C o m p a n y H e a d q u a rt e r s 1995 Sales C o m m e n t
US$ millions
Glaxo We l l c o m e U K $ 1 1 . 8 0
M e rc k U S A $ 1 0 . 9 6
N o v a rt i s S w i t z e r l a n d $ 1 0 . 9 4 Ciba-Geigy and Sandoz combined
H o e c h s t G e rm a n $ 9 . 4 2
R o c h e S w i t z e r l a n d $ 7 . 8 2
Bristol-Myers Squibb U S A $ 7 . 8 1
P f i z e r U S A $ 7 . 0 7
SmithKline Beecham U K $ 6 . 6 0
Johnson & Johnson USA $ 6 . 3 0
P h a rmacia & Upjohn S w e d e n $ 6 . 2 6
Source: Wall St. Journal, 7 March 1996. Company sales exclude sales of nondrug products.
70
The global market for animal health industry is almost $15 billion. In 1995, the
top 10 corporations accounted for 43% of global sales.
World’s Top 10 
Veterinary Pharmaceutical 
Corporations
Corporation 1995 Sales 
US$ millions
Pfizer Inc. (US) 1 , 2 0 0
M e rck Agvet 8 3 0
B a y e r 7 7 5
N o v a rt i s 7 5 0
Rhone Merieux, Inc. 6 0 0
Hoechst roussell Ve t 5 2 0
Elanco Animal Health 5 1 0
M a l l i n c k rodt Ve t e r i n a ry Inc. 4 6 0
Ft. Dodge Laboratories 4 4 0
P h a rmacia & Upjohn 3 8 0
Source: Feedstuffs, 29 July 1996
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C o m m e n t
Schering Plough acquires Canji.
Gates & Allen make $10 million equity
i n v e s t m e n t .
Corange Intl. makes $100 million re s e a rc h
a g reement; Genentech makes equity investment.
Sandoz (Novartis) acquires GTI) in 1995 for
$295 million.
L a rge-scale sequencing of human genome.
Synethelabo (France) makes $69 million
re s e a rch agreement and equity investment 
of $9.7 million. Focus on prostate cancer.
SmithKline Beecham made $125 million
re s e a rch agreement in 1995. Pioneer Hi-Bre d
has $16 million deal to map maize genes.
All subscribe to Incyte’s pro p r i e t a ry gene
sequence databases. Incyte claims its 
database partial sequences of nearly 100,000
genes (May, 1996). Pfizer and Pharmacia &
Upjohn are major investors in the company.
Eli Lilly has 5-yr. agreement valued at 
$69 million related to athero s c l e ro s i s .
Bayer – obesity, asthma and osteoporo s i s
gene discovery; Novartis – card i o v a s c u l a r
d rugs; Eli Lilly – license on breast cancer
g e n e .
Glaxo has 5-yr. R&D agreement on Type II
diabetes and obesity genes.
Genomic Company
Canji Inc. (USA)




Genetic Therapy Inc. (USA)
Genome Therapeutics Corp. (USA)
founded as Collaborative Research in 1961, 
changed name in 1994
Genset (France)
founded 1989




Millennium Pharmaceuticals Inc. (USA)
founded 1993




Corporate Part n e r s
Schering Plough
William Gates and Paul Allen (Micro s o f t )
Rhone Poulenc Rorer Inc.
Corange Intl. Ltd.
Genentech, Inc. (Hoffman-La Roche)
N o v a rt i s
Astra AB
Boehringer Mannheim
S c h e r i n g - P l o u g h
Synthelabo (France)
Genetic Therapy (Novart i s )
ISIS Pharm a c e u t i c a l s
Pioneer Hi-Bred Intl.
H o ffman-La Roche
SmithKline Beecham 
Ta k e d a
Abbott Labs
Hoechst Marion Roussel 
H o ffman-La Roche
Johnson & Johnson
Novo Nord i s k
P f i z e r
P h a rmacia & Upjohn
Z e n e c a
Eli Lilly & Co.
H o ff m a n - L a R o c h e
Astra AB
B a y e r
Ciba-Geigy (Novart i s )
Eli Lilly & Co.
Boehringer Ingelheim
Corange Intl.
G l a x o We l l c o m e
Genentech (Novart i s )
source: RAFI
APPENDIX E
The Pharmaceutical Industry & Human Genome Companies
APPENDIX F 
Glossary
Many of the following terms are highlighted in bold type the first time they
appear in the text.
Agenda 21
A comprehensive action plan on the environment adopted at the United Nations Conference on
E n v i ronment and Development in Rio de Janeiro, Brazil, in June 1992.
bilateral agreement
An agreement signed by two parties, including governments. 
biotechnology 
A variety of techniques that involve the use and manipulation of living organisms to make commerc i a l
p roducts. These techniques include cell culture, tissue culture, embryo transfer and recombinant DNA
technology (genetic engineering).
biological diversity or biodiversity 
All living organisms, their genetic material and the ecosystems of which they are a part. It is usually
described at three levels: genetic, species and ecosystem diversity. 
Genetic diversity is the variation of genes between and within species. It is all the genetic inform a t i o n
contained in the genes of all individual plants, animals and micro o rganisms on earth. Genetic diversity
within a species permits it to adapt to new pests and diseases, and to changes in environment, climate,
and agricultural methods. 
Species diversity is the total number or variety of species in a given area. 
Ecosystem diversity is the total variety of ecosystems or interdependent communities of species and their
physical environment. Ecosystems may cover very large or quite small areas. They include such natural
systems as grasslands, mangroves, coral reefs, wetlands and tropical forests, as well as agricultural
ecosystems that depend on human activity but have characteristic assemblages of plants and animals.
biopiracy 
The use of intellectual pro p e rty to legitimize the exclusive ownership and control of biological re s o u rc e s
and knowledge, without recognition, re w a rd or protection to informal innovators.
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of
Patent Procedure
An international treaty administered by the World Intellectual Pro p e rty Organization (WIPO) that has been
signed by 32 countries.
cell line
Cells removed from humans, or other organisms that are manipulated to sustain continuous, long-term
g rowth in an art i ficial culture. So-called immortal cell lines have been cultured to live indefinitely under
a rt i ficial conditions, where temperature and nutrient re q u i rements are strictly controlled. Cell lines pro v i d e
an inexhaustible supply of the DNA of the organism they are taken from (see Human Genome Diversity
P roject below).
centres of genetic diversity 
The locations where the world’s most common food crops are found to have the greatest genetic
d i v e r s i t y. Often called the Vavilov Centres after the Russian scientist who identified them in the early
1900s, they tend to be areas where crops have been cultivated longest and most widely, but are not
necessarily the centres of origin of crop species.
72
compulsory licensing
A legal mechanism that obliges patent holders to make their inventions available at equitable prices if
competitors can prove that patents are not being “worked” to the benefit of society or are not accessible
within a reasonable price range. 
Conference of the Parties (COP) to the Convention on Biological Diversity 
All the countries which have ratified the Biodiversity Convention. The COP meets periodically to discuss
and shape the implementation of the Convention. Meetings were held in the Bahamas in 1994 and in
Indonesia in 1995. The 1996 meeting is scheduled to take place in Arg e n t i n a .
Consultative Group on International Agricultural Research (CGIAR)
An informal network of sixteen International Agricultural Research Centres whose gene banks came under
the control of the UN Food and Agriculture Organization in October 1994. The centres are: 
• C I AT: Centro Internacional de Agricultura Tro p i c a l / I n t e rnational Centre for Tropical Agriculture, Colombia 
• CIFOR: Centre for International Fore s t ry Research, Indonesia 
• C I M M Y T: Centro Internacional de Mejoramiento de Maíz y Tr i g o / I n t e rnational Centre for the
I m p rovement of Corn and Wheat, Mexico 
• CIP: Centro Internacional de la Papa/International Potato Centre, Peru 
• ICARDA: International Centre for Agricultural Research in the Dry Areas, Syria 
• ICLARM: International Centre for Living Aquatic Resources Management, Philippines 
• ICRAF: International Centre for Research in Agro f o re s t ry, Kenya 
• I C R I S AT: International Crops Research Institute for the Semi-Arid Tropics, India 
• IFPRI: International Food Policy Research Institute, United States 
• ILRI: International Livestock Research Institute, Kenya 
• IIMI: International Irrigation Management Institute, Sri Lanka 
• I I TA: International Institute of Tropical Agriculture, Nigeria 
• IPGRI: International Plant Genetic Resources Institute, Italy 
• IRRI: International Rice Research Institute, Philippines 
• ISNAR: International Service for National Agricultural Research, Netherlands
• WARDA: West Africa Rice Development Association, Ivory Coast
Convention on Biological Diversity or Biodiversity Convention
A legally binding international agreement for the conservation and sustainable use of biodiversity. Its final
text was adopted in Nairobi on May 22, 1992. It was signed by over 150 countries at the UN Conference on
Environment and Development in Rio de Janeiro, Brazil, in June 1992 and was ratified by 128 governments
as of October 1995. The Convention came into force on December 29, 1994. The US had not ratified it as
of early 1996.
copyright
An intellectual pro p e rty right intended to protect artistic and cultural works, such as books, illustrations,
photographs, and television programs, from being duplicated or transmitted without the author’s
p e rmission. Copyrights do not give exclusive right to the ideas in protected material, but rather to the
s p e c i fic format in which they appear.
DNA (deoxyribonucleic acid)
The molecule in chromosomes that is the re p o s i t o ry of genetic information in all organisms (with the
exception of a few viruses in which the here d i t a ry material is ribonucleic acid or RNA). The inform a t i o n
coded by DNA determines the stru c t u re and function of an organism. 
ex situ conservation
L i t e r a l l y, conservation “off-site” or outside an org a n i s m ’s natural habitat. Gene banks and botanical
g a rdens are examples.
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Farmers’ Rights
In 1985, the UN Food and Agriculture Organization (FAO) Commission on Plant Genetic Resources (now 
the FAO Commission on Genetic Resources for Food and Agriculture) introduced the principle of Farm e r s ’
Rights. The FA O ’s International Undertaking on Plant Genetic Resources was amended in 1991 to include
F a rmers’ Rights. The amendment recognizes farmers as past, present and future in situ a g r i c u l t u r a l
innovators who collectively have conserved and developed agricultural genetic re s o u rces around the
world. Farmers are recognized as innovators entitled to intellectual integrity and to compensation
whenever their innovations are commercialized. Farmers have the right to Germplasm, Inform a t i o n ,
Funds, Technologies and Farming/Marketing Systems (GIFTS). Compensation was anticipated via a global
Gene Fund, paid into by the North for genetic conservation and improvement in the South. Agenda 21 and
the Biodiversity Convention have also adopted the principle of Farmers’ Rights. The government of India
is drafting legislation that would establish it in law. The financing and implementation of Farmers’ Rights
will be addressed by several international agricultural meetings in the coming years. 
General Agreement on Tariffs and Trade (GATT) 
The GATT was established in 1947 and grew from a club of 23 industrialized nations to an agre e m e n t
between 115 signatory states. Following the Uruguay Round of negotiations (concluded in 1994), GAT T
came under the management of the multilateral World Trade Organization on January 1st, 1995 (see
below). The Uruguay Round included an agreement on intellectual pro p e rty as a trade issue, known as
Trade Related Intellectual Pro p e rty Rights or TRIPS (see below).
gene
The functional unit of here d i t y. A gene is a section of DNA that codes for a specific biochemical function
in a living being. Genes are physically located on chro m o s o m e s .
genetic engineering 
The use of high technology processes to manipulate the DNA of living organisms in order to create new,
d i ff e rent organisms in a laboratory. 
genome 
All the genetic material in the chromosomes of a particular organism or species.
gene bank
A form of ex situ c o n s e rvation for plant, seed, and animal germplasm. Gene banks are usually humidity-
and temperature - c o n t rolled facilities where seeds and other re p roductive materials are stored for future 
use in re s e a rch and breeding programs. Gene banks that stock crop germplasm are also called seed
banks. Though very important, they are a poor replacement for the maintenance of crop genetic diversity
in situ or on-site. 
germplasm
The total genetic variability, re p resented by germ cells or seeds, available to a particular population of
o rg a n i s m s .
Green Revolution
A massive and controversial agricultural re s e a rch and production strategy which aimed to increase the
output of staple grains in the South starting in the 1960s. Initially funded by the Rockefeller Foundation, 
it was later supported by aid from Nort h e rn governments. The Green Revolution was based on the belief
that world hunger was basically a technical problem which could be fixed by raising agricultural production
t h rough higher-yielding varieties. This assumption and approach have dominated agricultural aid for thre e
decades. The Green Revolution’s critics have pointed out the political and economic causes of hunger, the
need for land reform, and the need for other structural changes in agriculture and consumption worldwide.
At its peak, the Green Revolution produced high-yielding varieties of a few staple crops. Unlike most
f a rm e r’s varieties, however, these new plants were designed to be highly dependent on expensive and
often environmentally unsound chemical inputs. Large scale, capital-intensive agriculture reaped the
benefits while smaller farmers were marginalized, increasing social tensions and working against in situ
c o n s e rvation. Many of the agricultural re s e a rch centres of the Consultative Group for Intern a t i o n a l
Agricultural Research (see above) contributed to or were formed as a result of the Green Revolution.
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Human Genome Project
An international collaborative endeavour among geneticists to “map the human genome” by using new
technologies to describe the chemical composition of an estimated 100,000 genes that control the
inherited part of human beings’ makeup. 
Human Genome Diversity Project (HGDP)
“A collaborative research project … being developed on a global basis under the auspices of the Human
Genome Organization.” Its goal is “to arrive at a … more precise definition of the origins of different world
populations by integrating genetic knowledge … with knowledge of history, anthropology and language.”
One of its expected uses is to provide information on the role played by genetic factors in the pre d i s p o s i t i o n
or resistance to disease. Concretely, the HGDP plans to draw and immortalize human cell lines from
hundreds of indigenous peoples worldwide. 
Human Genome Organization (HUGO)
The international umbrella organization that manages the Human Genome Project. In the US it is primarily
funded by the Department of Energy and the National Institutes of Health. In Europe, HUGO is funded by
the European Commission.
in situ conservation
L i t e r a l l y, conservation “on site.” In situ c o n s e rvation is the conservation of ecosystems and natural
habitats, and the maintenance, re c o v e ry and development of viable populations of species in their natural
s u rroundings. In the case of domesticated livestock or cultivated crop species, it is their conservation in
the surroundings where they have developed their distinctive pro p e rt i e s .
Intellectual Property (IP) or Intellectual Property Rights (IPR)
Laws that grant monopoly rights to those who create ideas or knowledge. They are intended to pro t e c t
inventors against losing control of their ideas or the creations of their knowledge. There are five major
f o rms of IPR: patents, plant breeders’ rights, copyright, trademarks, and trade secrets. (See other entries
in the Glossary for definitions of each.) All IPRs operate by exclusion, granting temporary monopoly
rights which prevent others from making or using the creation. IP legislation is national, although most
countries adhere to international conventions governing intellectual pro p e rt y.
International Undertaking on Plant Genetic Resources for Food and Agriculture
A multilateral instrument called the International Undertaking on Plant Genetic Resources was adopted 
by the United Nations Food and Agriculture Organization in 1983. In 1995 the name was changed to 
the International Undertaking on Plant Genetic Resources for Food and Agriculture. The Undertaking is
c u rrently being re-negotiated to bring it in line with the Convention on Biological Diversity. It is a
v o l u n t a ry agreement intended to provide an international framework for the collection, conserv a t i o n ,
exchange and utilization of plant genetic re s o u rces for food and agriculture. 
life industry
An industry that has arisen through mergers and cooperative agreements among corporations to pro fit
f rom the manipulation and ownership of living organisms. With the development of biotechnology and the
i n c reased use of intellectual pro p e rty systems, these previously discreet agrochemical, seed, pharm a c e u t i c a l ,
and food industries increasingly depend upon a similar set of technologies and laws which allow the
monopoly control of living organisms. 
microorganisms (or microbes)
Tiny living things that are not visible except with a microscope. These include algae, bacteria, fungi
(including yeasts), certain protists (one celled organisms that are not bacteria), and viruses. For the
purpose of patent protection, the term micro o rganism often applies to other types of biological material,
including cell lines of plants and animals, and human genetic material. There is considerable uncert a i n t y
re g a rding the scope of the term .
multilateral agreement
An agreement among many parties, such as an international agreement signed by many of the world’s
g o v e rn m e n t s .
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Paris Union on Industrial Property 
The principal inter- g o v e rnmental body established to govern the patent system and determine the gro u n d
rules for patents. In recent years its re g u l a t o ry capacity has been overwhelmed by national patent off i c e
decisions in the United States and Europe. It is likely to be further undermined by the new TRIPS
a g reement (see below).
patent
A legal monopoly that covers a wide range of products and processes, including life forms. To be patentable,
inventions must meet three basic criteria. They must be: (1) novel , that is, they must not have been known
p reviously to the public; (2) useful, that is, they must do what they claim, though they need not necessarily
be practical; and (3) non-obvious, that is, they must have an “inventive step” and constitute some notable
extension of what was previously known. Patents provide exclusive legal protection to patent holders,
usually for 17 to 25 years. Anyone wishing to use a patented invention must receive permission from the
patent holder and often must pay a royalty. In exchange for this monopoly, the patent holder must disclose
or describe the invention.
Patent Cooperation Treaty 
An eff o rt to create a global patent system to ensure that a patent granted in one country will be adopted 
in all member countries. It has not yet achieved its goal. The treaty has 77 member states, including all
industrialized countries, ten former French colonies in Africa, two countries from the Americas and 
eight from Asia. It is likely to become less relevant with the adoption of TRIPS under the World Tr a d e
O rganization (see below).
Patent Culture Depository
An institution for the deposit of micro o rganisms subject to patent claims. Twenty six such institutions in 
15 countries have been recognized by the Budapest Treaty on the International Recognition of the Deposit
of Micro o rganisms for the Purposes of Patent Pro c e d u re (see above). These institutions contain the living
materials (micro o rganisms, genes, seeds, animal embryos, human and animal cell lines, etc.) that are the
basis of virtually all patents on living material.
plant breeders’ rights (PBR)
A form of intellectual pro p e rty law that grants a plant bre e d e r’s cert i ficate to those who breed new plant
varieties. Plant breeders’ rights generally contain breeders’ and re s e a rch exemptions that allow non-
commercial use of protected varieties. In the US, recent court decisions have threatened these exemptions.
T h e re are currently two international agreements governing PBR, both of them under UPOV, the Intern a t i o n a l
Convention for the Protection of New Plant Varieties (see below).
sui generis legislation
Literally “of its own kind”, that is, in a class alone. This refers to any unique form of intellectual property
legislation specifically designed to meet certain needs.
trade secret
An intellectual property right used when inventors do not wish to patent in order to protect themselves
from competitors. Unlike patents, trade secrets do not require inventors to publish and have no time limit.
They can be maintained, for example, by contracts with company employees who are legally bound not to
disclose the protected information.
trademark
A form of intellectual property right that provides legal monopoly for a name, or a linguistic or visual
symbol.
transgenic organism
Any organism that has been genetically engineered to contain a gene from another organism, usually
f rom a diff e rent species.
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Trade Related Intellectual Property Rights (TRIPS)
TRIPS is a GATT agreement, now administered by the World Trade Organization (WTO), stipulating that 
all signatories must conform to industrial country standards of intellectual pro p e rty law. TRIPS re q u i re s
signatories to introduce patent coverage for micro o rganisms and to have some form of intellectual
p ro p e rty coverage for plants. Developing countries have until at least the year 2000 to implement the
a g re e m e n t ’s intellectual pro p e rty provisions. Least developed countries have until 2004, with a possible
extension. The WTO will review the TRIPS agreement in 1999, and it could be modified as a re s u l t .
Union for the Protection of New Varieties of Plants (UPOV) 
A Geneva-based organization established under the World Intellectual Property Organization in 1961 to deal
with plant breeders’ rights. It has 30 members and seven others have initiated proceedings to join. There
are two operative UPOV Conventions dated 1978 and 1991. The 1978 Convention allows farmers to save
and replant PBR-protected seed from their harvest. The 1991 version restricts the right of farmers to save
seed and makes plant breeders’ rights more like patents, extending the scope of the monopoly granted to
the cert i ficate holder. As of January 5th, 1996, Australia, Denmark, Israel and Slovakia had ratified the more
restrictive 1991 Convention. The UPOV Council meets every October, after a series of inter-governmental
and government/industry committee meetings that regulate the Conventions’ evolution. Many countries of
the South are preparing to join UPOV.
World Intellectual Property Organization (WIPO) 
The Geneva-based organization that houses 20 intellectual pro p e rty conventions adopted by signific a n t
parts of the world community, including conventions on patents, plant breeders’ rights, and the Budapest
Treaty on IPR over biological materials. WIPO has 151 state members, including all industrialized countries
and many countries of the South. The annual WIPO Council includes all members and observers. Each
convention has its own membership and forum under the WIPO umbrella. The Director General of WIPO is
usually the Secretary General of the individual conventions, but day-to-day operations are generally carried
out by a specialist secretariat led by a Deputy Secretary General.
World Trade Organization 
A body created at the conclusion of the Uruguay Round of GATT in 1994 to monitor the GATT agre e m e n t
and pursue global trade objectives. It became operational on January 1st, 1996. It now has the potential to
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